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The current standard of care in genetic testing for hereditary cancer syndromes is to offer genetic 
testing to individuals who meet certain criteria based on personal and/or family history of cancer. 
With the recent advances in testing technology, it has become feasible to consider genetic testing 
on a wider scale. There has been a debate by experts in the field of cancer genetics of whether 
the family history-based approach should be supplemented or replaced with a population-
screening based approach. The purpose of this study was to examine the interest level and 
motivations of individuals in the general population for genetic testing of genes associated with 
hereditary cancer as well as identify psychosocial implications. This study surveyed individuals 
in the dominant market of crowdsourcing used by researchers in the academic setting, Amazon 
Mechanical Turks.  
The majority of the participants in this study (73%, n = 861) indicated that they would 
currently be interested in taking a genetic test for cancer. After this initial interest question, the 
participants were presented with six possible result scenarios. After the scenarios were presented, 
the participants were again asked a question regarding interest level in genetic testing for 
hereditary cancer. Of the 861 participants who answered this question, 40 (4.9%) of those who 
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initially indicated an interest on having genetic testing for hereditary cancer at some point in life, 
stated that they would never take such a genetic test. This data suggests that the need for 
informed consent and patient understanding of the test is needed. The survey responses indicated 
a wide variety of emotional and psychological stresses may occur as a result of genetic testing 
and indicates the need for additional support and resources to be in place before the 
implementation of a population-screening program for any genes related to hereditary cancer. A 
population-screening program for hereditary cancer would be a public health intervention with 
the goal of identifying all mutation-carriers. However, there could possibly be serious medical, 
psychosocial, ethical and legal ramifications should such a program like this be implemented 
before more research and serious thought is given into the proper infrastructure.  
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1.0  INTRODUCTION 
Since genetic testing for hereditary cancer syndromes such as Lynch syndrome (LS) and 
Hereditary Breast and Ovarian Cancer syndrome (HBOC) was first offered on a clinical basis, 
personal and family history guidelines and criteria have been established and continuously 
refined about who should be offered genetic testing. Genetic testing for hereditary cancer 
syndromes can currently be ordered by either physicians or licensed genetic counselors in certain 
states. Individuals found to carry a mutation in a gene associated with a significantly increased 
risk of cancer over that of the general population should take preventative measures such as 
increased screening, chemoprevention, and/or prophylactic surgery if these options are available 
for the organ or tissue at this increased risk. If an unaffected individual is found to carry a 
mutation in one of these genes, then the clinical goal is to either prevent cancer entirely using 
prophylactic measures or detect it at an early, more treatable stage.  
The prevalence of BRCA1/2 mutations in the general population is estimated to be 
between 1 in 300 to 1 in 500 people1. There have recently been a few studies in the Ashkenazi 
Jewish population, where the prevalence of BRCA1/2 mutations is increased ten-fold, which 
suggest that the current genetic testing strategy misses approximately half of the Ashkenazi 
Jewish carriers of BRCA1/2 mutations23. It has been suggested that this data could be 
extrapolated and applied to the population at large, though there are currently no published 
studies replicating these findings in non-Ashkenazi Jewish populations.  
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Some experts have used the data in these studies to propose support for population-
screening programs for BRCA1/2 mutations in order to identify individuals who would not 
otherwise be identified using current genetic testing strategies and then manage them 
appropriately4. In 2014, the Lasker-Koshland Special Achievement Award in Medical Science 
was presented to Dr. Mary-Claire King for her work specifically related to the BRCA genes. 
Using this platform, Dr. King was able to gain substantial attention and awareness of her team’s 
research studies of population-based screening and their viewpoint of offering genetic screening 
of BRCA1 and BRCA2 to every woman in the United States over the age of 304. Benefits to a 
population-screening based approach would include identifying mutation-carriers who 
previously would not have been identified and using prevention and management strategies to 
prevent cancer or detect it at an early stage and ultimately save lives5. Limitations and risks to a 
population-screening based approach include not obtaining proper informed consent before 
genetic testing, possible psychosocial effects, a sense of false-security for those who test 
negative, and potential ethical and practical implications6. 
There is a growing body of literature about the potential clinical utility and cost-
effectiveness of using genomics to guide screening for the general population as well as some of 
the practical and ethical uncertainties. Several studies have also been published on the topic of 
current population-based genetic testing available such as newborn screening and carrier testing. 
However, there is little published on the interest level, knowledge, and/or attitudes of individuals 
in the general population in the United States for cancer susceptibility genetic testing. This 
research study was conducted to fill a gap in the current literature about the interest level and 
possible psychosocial effects from individuals in the general population in the United States on 
the topic of offering genetic testing for hereditary cancer genes to the general population. 
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1.1 SPECIFIC AIMS AND RESEARCH QUESTIONS 
1.1.1 Specific Aims 
Aim 1: Examine the interest level of individuals in the public (represented by the Amazon Turks 
Community) in taking a genetic test for hereditary cancer. 
Aim 2: Use various possible scenarios in the context of population screening to evaluate the 
possible psychosocial impacts of genetic testing, specifically in this setting, using quantitative 
methods.  
1.1.2 Research Questions 
Question 1: Are individuals in the general population interested in a genetic test that analyzes 
genes associated with hereditary cancer syndromes? 
Question 2: What are some possible psychosocial implications of a population-screening 
program for hereditary cancer syndromes? 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 CANCER 
In the United States, approximately one in four deaths are due to cancer7,8. According to the 
National Cancer Institute, the lifetime risk of developing cancer is 43.31% for males and 37.81% 
for females in the United States9. These risks apply to the general population as a whole; 
however, each individual can have a different, individual risk for developing cancer depending 
on their own personal risk factors. These risk factors include several lifestyle and environmental 
factors such as tobacco use, alcohol use, obesity, lack of physical activity, ionizing radiation, 
environmental pollutants, infections, as well as inherited genetic factors10.  
2.1.1 Cancer Screening Approaches for the General Population 
Traditionally, cancer-screening recommendations for the general population have the goal of 
diagnosing cancer when it is at an early, more treatable stage. There are well-established 
guidelines in place for the general population, or those who have an average risk for cancer, as to 
when cancer screenings such as mammograms and colonoscopies should take place. Cancer is 
typically a disease of aging, and the recommendations for the general population reflect that as 
many of the recommended screenings do not begin until closer to the typical age of diagnosis. 
For example, the American Cancer Society recommends annual mammograms starting at 45 
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years of age and colonoscopies every 10 years starting at 50 years of age for individuals at 
average risk for breast and colon cancer11,12. The guidelines and management recommendations 
for these cancer population screening programs, such as mammograms and colonoscopies, weigh 
the benefit of saving lives by diagnosing cancer early with the risks and costs of these screening 
procedures to settle on an appropriate age to start screening as well as how often these screenings 
should occur13. These screening recommendations also take into account the incidence of cancer 
at a given age and whether or not the screening is effective at increasing survival rates13. 
2.1.2 Categories of Cancer 
All cancers develop as a result of genetic mutation, however most cancers are not the result of a 
single inherited mutation14. Typically, cancer forms as these genetic mutations are accumulated 
over time in certain parts of the body, either by chance or as a result of environmental or lifestyle 
exposures15. More rarely, genetic mutations in specific genes can be inherited and are then 
present in all of the cells of the body, causing an increased risk of cancer in the tissues in which 
that specific gene primarily functions. There are certain genes that, when working properly, 
prevent cancer from forming. These genes generally fall into one of two categories: tumor 
suppressor genes or proto-oncogenes.  
Inherited mutations in one copy of a tumor suppressor gene, coupled with a “second hit” 
on the other copy, acquired somatically, leads to uncontrolled cellular division and oftentimes a 
tumor16. Mutations in these genes can facilitate cancer development because these genes are not 
able to perform their normal function and prevent cancer from forming16. An acquired mutation 
in specific positions of an oncogene, can lead to aberrant or overactive functioning of the 
resultant protein, which similarly causes uncontrolled cell growth. BRCA1 and BRCA2 are both 
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tumor-suppressor genes and function to assist in DNA repair, specifically in transcriptional 
regulation of genes that are involved in apoptosis, the cell cycle, and DNA repair. This 
transcriptional regulation is in response to damage to DNA17. The RET gene, which causes 
Multiple Endocrine Neoplasia type 2 (MEN2) is an example of an oncogene. Oncogenes can 
contribute to an increased risk of cancer by allowing some cells which normally would have 
gone through apoptosis to survive and proliferate instead14. 
Cases of cancer can be divided into three different categories, sporadic, familial 
predisposition, and hereditary predisposition18. Current data suggests that the majority of cancer 
(~60%) is sporadic and happens by chance as a result of a lifetime of exposure to a combination 
of lifestyle factors, environmental factors, or chance DNA replication errors15. Over time, these 
random mutations can lead to the accumulation of genetic mutations in a certain tissue, most 
often activating an oncogene, and causing a tumor15.  
Approximately 30% of cancers can be considered familial and are thought to have 
happened as a result of both genetic and environmental factors10. Oftentimes individuals/families 
that fall into the familial category have a clustering of cancers, where cancer seems to be 
happening more often than by chance alone, but is not characteristic of hereditary cancer15. 
Individuals in the familial category have a moderately increased risk of certain cancers and may 
be screened slightly earlier and/or slightly more often than those at the average risk of the 
general population. The last category of cancer is hereditary cancer predisposition, where a 
single inherited germline mutation (or very rarely, a de novo mutation) causes an increased risk 
of cancer. 
Hereditary cancer makes up approximately 5 – 10% of all diagnoses of cancer19. 
Oftentimes, individuals with hereditary cancer in their family have striking personal or family 
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histories of cancer. There are certain characteristics that are commonly seen in cases of 
hereditary cancer. These characteristics are: younger ages of onset (<50 years of age), bilateral 
cancers, certain tumor types (e.g. triple-negative breast cancer), rare cancers (e.g. male breast 
cancer, ovarian cancer, chromophobe renal cell carcinoma), multiple family members on the 
same side of the family with the same or related types of cancer, suggestive tumor studies (e.g. 
colon cancer due to Lynch syndrome), and certain ethnic groups (e.g. the Ashkenazi Jewish 
population for BRCA genes)1. The presence or absence of these characteristics is used by genetic 
counselors and other healthcare providers to assess an individual’s personal cancer risk and may 
also be used to assess an individual’s chance of having a mutation and determine whether genetic 
testing is appropriate.  
Most of the known hereditary cancer syndromes are inherited in an autosomal dominant 
pattern. This means that both men and women can carry these mutations and that only one of the 
two copies of the associated gene needs to have a mutation to cause an increased risk for cancer. 
If an individual has a mutation in one of these genes, there is a 50% chance of passing on the 
mutation and the increased risk for cancer onto his/her children15. In the case of a hereditary 
cancer mutation, this mutation was most likely inherited from one of the individual’s parents. In 
the case of an inherited mutation, and not a de novo mutation, there is a 50% chance for each 
sibling to have inherited the mutation as well.  
2.1.3 Cancer Screening Approaches for High-Risk Individuals 
Individuals with a significant personal or family history of certain cancers or a known genetic 
mutation in a moderate to high-risk gene, are typically classified as high-risk individuals and 
have a significantly increased risk of cancer over the general population. There are different 
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guidelines in place for the management and screening of these individuals20,21,22,1. Those with an 
increased risk of cancer based on family history or a genetic mutation are typically screened 
starting at earlier ages and using shorter time intervals. Other options such as prophylactic 
surgery or chemopreventive drugs may also be available for high-risk individuals depending on 
the organ or tissue at risk23. Currently, the identification of pre-symptomatic, high-risk 
individuals is the result of a significant family history of cancer and/or a family member who had 
genetic testing where a mutation was identified.  
 Using the BRCA genes as an example, the risks for cancer are approximately a 57% 
lifetime risk of breast cancer, and for ovarian cancer the lifetime risk is approximately 18% for 
BRCA2 mutation carriers and 40% for BRCA1 mutation carriers24. Other increased cancer risks 
in mutation positive BRCA individuals include male breast cancer, prostate cancer, pancreatic 
cancer, and melanoma25. It has been found that women who are classified as being at high-risk to 
develop breast cancer reduce their risk by 90 – 94% by having a prophylactic mastectomy1,26 and 
risk-reducing bilateral salpingo oophorectomies have been shown to decrease the risk of both 
breast cancer and ovarian cancer27,28.  
2.2 GENETIC TESTING OF HEREDITARY CANCER GENES 
Since its advent in 1996, clinical genetic testing for BRCA1/2 mutations has been offered to 
select individuals meeting certain criteria. This testing strategy has continued and is still the 
current strategy for identifying who should be offered genetic testing; a family history-based 
approach. It is common practice by physicians, genetic counselors, and some insurance 
companies to either follow the National Comprehensive Cancer Network (NCCN), the American 
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College of Medical Genetics and Genomics (ACMG) and National Society of Genetic 
Counselors (NSGC) joint practice guidelines, the US Preventive Services Task Force or the 
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group 
recommendations for referral and testing criteria to identify the appropriate individuals who may 
benefit from genetic testing1,21,29,22. Using the current testing strategy, goals of cancer genetic 
counseling include a discussion of the important elements of the benefits and risks/limitations of 
genetic testing with the patient prior to testing, proper informed consent, and helping the patient 
understand what to expect from the genetic testing and the possible effects on medical 
management.  
2.2.1 Possible Test Results of Genetic Testing 
When genetic testing for hereditary cancer syndromes is performed, there are typically three 
possible test results. These possible test results are: “positive,” “negative,” and “variant of 
uncertain significance” (VUS). The positive result means that when the lab performed the 
sequencing and/or deletion and duplication analysis of the requested genes, a mutation was 
identified, and that mutation is harming the function of the gene which causes an increased risk 
for certain cancers. A negative result means that no mutations were identified in the requested 
genes. A negative result can be a true negative, meaning that a mutation that has previously been 
identified in another family member has not been found in the patient. In this scenario, the 
individual who tested negative would have the same cancer risks as the general population. If a 
mutation has not been previously identified in a family and the individual’s genetic testing is 
negative, then that individual would be managed based on personal and/or family history of 
cancer. In this case, there is not currently a genetic answer for their personal and/or family 
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history of cancer but some of the chance that they have a hereditary cancer syndrome would be 
eliminated. 
2.2.1.1 Variants of Uncertain Significance 
A variant of uncertain significance (VUS) is not a straight-forward answer, but rather an 
inconclusive result. If an individual undergoes genetic testing and a VUS is found, this means 
that the lab analyzed the requested genes and found a change in the DNA code of the gene, but 
there is not enough data for the lab to be able to classify this change as either a positive or 
negative result. The most common type of VUS are missense substitutions which result in a 
single amino acid change30. In the case of an individual having a VUS, he/she is usually followed 
solely based on his/her personal and/or family history of cancer and genetic testing is not offered 
to other relatives outside of a research protocol31,15. A VUS may be reclassified as more research 
on specific changes in these genes occurs in the future. Oftentimes a VUS is reclassified as a 
benign polymorphism (negative result), but they are occasionally reclassified as a pathogenic, 
disease-causing mutation as well (positive result).  
 The American College of Medical Genetics and Genomics (ACMG) has standards and 
guidelines for how to classify and interpret such variants32. Individuals undergoing genetic 
testing often have a pre-counseling session where they are informed of the three possible test 
results as well as the risk of getting a VUS back as a result, and what that would mean for them. 
As more data has been collected and classification schemes for variants have been updated, there 
has been a decrease in the VUS rate at many genetic testing laboratories, and this decreasing 
VUS rate trend is expected to continue as more individuals undergo genetic testing33.  
 The chance of a patient having a VUS result depends on what specific genes were 
ordered as well as how many genes were analyzed. BRCA1/2 genes have a lower rate of VUS 
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results due to how well-characterized they both are compared to many of the other genes known 
to be associated with hereditary cancer34. The VUS rate also depends on the laboratory 
performing the genetic testing. For instance, Myriad Genetics currently quotes their 2013 VUS 
rate as 0.6% for BRCA1 and 1.6% for BRCA2 on their website35. Ambry Genetics36 currently 
quotes their VUS rate for BRCA1/2 combined as 3.64% on their website and published a paper in 
2014 where 2,079 patients underwent panel genetic testing for 14 – 22 cancer susceptibility 
genes, not including BRCA1/2, and found a VUS rate of 15.1 – 25.6% depending on the panel 
ordered33.  
 There are higher rates of detecting a VUS in certain ethnic populations where relatively 
few individuals have undergone genetic testing6. As stated by Yurgelun et al., 20156 “cancer 
genetics is one area of modern medicine in which pervasive racial and ethnic disparities in health 
care access, delivery, and quality are especially prevalent.” Studies into these disparities have 
found that when comparing women of white ethnicity to women of minority ethnicities, minority 
women are less likely to be aware of genetic testing and/or referred for genetic testing and are 
more likely to have an inconclusive, VUS result due to the lack of data on non-white and non-
Ashkenazi Jewish ethnic populations37,38,39,40. While a population based screening program for 
hereditary cancer syndromes may expand access to these tests in minority populations, it is 
important to note that these individuals would be more likely to receive a VUS result, which may 
cause increased worry and anxiety, especially in the early stages of a screening program37.  
 Another concern in the case of a VUS may be that an individual makes a radical medical 
decision based on this result. A study by Vos et al., 201241 found that variants of uncertain 
significance were often inaccurately perceived and usually overestimation were made in cancer 
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risks. Due to this misperception, some individuals had made radical medical decision (such as 
surgery) based on a VUS. 
2.2.2 Informed Consent for Cancer Susceptibility Testing 
There are proposed basic elements of informed consent for cancer susceptibility testing. The 
American Society of Clinical Oncology (ASCO) first released a statement on the subject of 
genetic testing for cancer susceptibility in 1996. The proposed basic elements have had multiple 
updates and revisions since that time. These basic elements currently include information on the 
specific genetic mutation(s), possible effects on medical care, risk to other family members, 
psychological implications, confidentiality problems, and implications in the case of a positive, 
negative, and uninformative result31. There are additional informed consent components in the 
case of pretest counseling for a multi-gene panel which include specific attention to explaining 
the possible limited clinical utility in the case of a mutation found in a newer, and lesser-
understood gene, the high rate of variants of uncertain significance, and highlight possible 
implications for reproduction for genes that are associated with recessive disorders such as 
Fanconi Anemia31. 
2.2.3 Population-Screening Based Approach to Genetic Testing 
Recently, there has been a discussion in the literature and in the medical/research community as 
a whole of whether the current family history-based approach should be supplemented with a 
population-screening approach. This discussion has primarily revolved around the BRCA1/2 
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genes. In 2014, a recommendation was made by Mary Claire-King and her research group that 
all women in the United States age 30 and older should be offered BRCA1/2 testing4.  
Population screening for hereditary cancer syndromes has several implications. These 
implications are both clinical and psychosocial in nature. Population screening has the potential 
to identify those who do not meet the current testing criteria, do not have knowledge of their 
family histories, or do not know about/cannot access genetic testing services but in fact are 
carriers of a mutation in a gene associated with hereditary cancer.6 
 Many of the studies specifically related to BRCA1/2 have focused on the Ashkenazi 
Jewish population, as mutations in BRCA1/2 are much more common in this population 
(approximately 1 in 40) than in the general population where the prevalence is approximately 1 
in 300 to 1 in 50042,43,1. For example, a study took place in the Ashkenazi Jewish (AJ) population 
of Israel where DNA samples from 8,195 male subjects were genotyped for the three founder AJ 
mutations in BRCA1 and BRCA2. This study found that 175 of the 8,195 (2.14%) men were 
carriers of at least one of these mutations. Approximately half (85 out of 167) of the BRCA 
mutation carriers had little or no family history of a relevant cancer 2. This study concluded that 
population-based genetic testing in the Ashkenazi Jewish population may detect up to 56% more 
BRCA carriers compared with the current gold standard of family history-based genetic testing3. 
More data in this area of genetics is needed before this data can be extended to making the same 
conclusions about the general population at large. 
 It is also important to note that the genetic testing completed in these studies was a 3-site 
analysis for the founder mutations found in the Ashkenazi Jewish population. The VUS rate for 
3-site analysis is nearly negligible at this point in time. However, population screening in the 
general population would require full sequencing and deletion/duplication genetic testing to 
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capture mutation carriers as there are not founder mutations for the general population. With a 
VUS rate at best currently at 2.2% for BRCA1/2, population screening would identify 
approximately many more individuals with inconclusive results of variants (approximately 1 in 
45) of uncertain significance than pathogenic mutation carriers (approximately 1 in 400)6,44. 
 King et al45,4have recommended that only clear, positive results should be reported to 
individuals undergoing genetic testing in a population-screening context and that VUS results 
should not be reported, and considered to be negative. This is a controversial position because 
while most of the variants of uncertain significance are later reclassified as benign, there would 
be potential for legal, ethical, psychological, and medical ramifications in the instances where a 
VUS result is reclassified as pathogenic6.  
2.3 POPULATION SCREENING 
2.3.1 Principles of Population Screening 
The principles and goals of population screening were first developed and described in 1968 by 
Wilson and Jungner46. As stated by Khoury et al., 200347 “These principles emphasize the 
importance of a given condition to public health, the availability of an effective screening test, 
the availability of treatment to prevent disease during a latent period, and cost considerations.” 
These initial principles and goals have been further elaborated and defined in the last five 
decades. The principles from Wilson and Jungner46 have been used to guide policies regarding 
the use of genetic testing in a population screening program. In the United States, newborn 
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screening and carrier testing are examples of the use of genetic testing in population screening 
programs. 
‘Genetic Screening: Programs, Principles, and Research’ is the report of the Committee 
for the Study of Inborn Errors of Metabolism (SIEM Committee) which was published in 1975, 
three years after the Committee’s first meeting in August of 197248. In this report, the Committee 
stated: “As new screening tests are devised, they should be carefully reviewed. If the 
experimental rate of discovery of new genetic characteristics means an accelerating rate of 
appearance of new screening tests, now is the time to develop the medical and social apparatus to 
accommodate what later on may otherwise turn out to be unmanageable growth.” The general 
recommendations of the Committee are still used today49 and are quoted below48. 
 
 
Recommendations of the SIEM Committee for Genetic Screening: 
“Genetic screening when carried out under controlled conditions is an appropriate form of 
medical care when the following criteria are met: 
1) There is evidence of substantial public benefit and acceptance, including acceptance 
by medical practitioners. 
2) Its feasibility has been investigated, and it has been found that benefits outweigh 
costs, appropriate public education can be carried out, test methods are satisfactory, 
laboratory facilities are available, and resources exist to deal with counseling, follow-
up and other consequences of testing. 
3) An investigative pretest of the program has shown that costs are acceptable, education 
is effective, informed consent is feasible, aims of the program with regard to the size 
of the sample to be screened, the age of the screenees, and the setting in which the 
testing is to be done have been defined, laboratory facilities have been shown to 
fulfill requirements for quality control, techniques for communicating results are 
workable, qualified and effective counselors are available in sufficient number, and 
adequate provision for effective services has been made.  
4) The means are available to evaluate the effectiveness and success of each step in the 
process.” 
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2.3.2 Current Genetic Population Screening Programs 
2.3.2.1 Newborn Screening 
At birth, all infants born in hospitals in the United States use a heel-stick test to screen for a 
number of conditions. The disorders on a newborn screening panel are determined at the state 
level and vary from state to state, though there are 28 “core” conditions which all states screen 
for50. The technology used in the testing (Guthrie assay, tandem mass spectrometry, etc.) is also 
decided by each state and may vary from state to state47. According to the National Institute of 
Health, the intent of newborn screening is to detect conditions in newborns that can be 
debilitating or fatal but where outcomes can be improved if treatment is started early51. This is 
often before the newborn shows signs or symptoms of these conditions.  
 The Discretionary Advisory Committee on Heritable Disorders in Newborns and 
Children was chartered in April 2013 and has since made recommendations for a recommended 
uniform screening panel (RUSP) in order to combat the lack of consistencies between states. All 
states use this recommended panel at the minimum and some have chosen to include additional 
disorders not on the RUSP. Recently there has been much controversy surrounding the addition 
of metabolic/lysosomal storage disorders not on the RUST to state newborn screening panels 
because many do not have treatments. Furthermore, the screening for these conditions 
themselves has not been proven to be effective and thus do not meet the recommendations made 
by William and Jungner or by the SIEM Committee for population screening52. 
2.3.2.2 Carrier Screening for Single Gene Disorders 
The first genetic condition for which community-based screening programs for autosomal 
recessive genetic conditions were utilized was Tay-Sachs disease53. Programs screening for Tay-
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Sachs disease were initiated in 1971 and have since become an example for other programs due 
to the success in reducing the incidence of babies born with Tay-Sachs47. Carrier screening for 
many autosomal recessive genetic conditions are now made available to couples who are 
expecting a baby. Testing for certain conditions offered typically depends on the ethnicity of the 
soon-to-be parents and/or family history. For example, those of Mediterranean descent can be 
offered thalassemia carrier testing and pregnant women of any ethnicity should be offered cystic 
fibrosis carrier testing47.  
 Carrier screening for certain conditions can be ordered by physicians or licensed genetic 
counselors and has also more recently become available through direct-to-consumer genetic 
testing labs. For example, the company 23andMe offers genetic testing of a few common 
mutations for 36 autosomal recessive conditions that consumers can order directly from 
23andMe. 
2.4 DIRECT TO CONSUMER GENETIC TESTING 
Direct-to-consumer (DTC) genetic testing was first introduced in 2006 and allows an individual 
in the general population to order a genetic test directly from a lab, without the ordering medium 
of a physician or other healthcare professional such as a genetic counselor54. Those in favor of 
DTC genetic testing have argued that consumers should have the ability to access their own 
personalized risk information in order to empower the consumer to have the knowledge about 
diseases risks and motivation to make lifestyle and/or treatment choices that may prevent the 
disease54. However, concerns have arisen from professional organizations, governmental 
regulators, and other experts in the field. The professional organizations include the American 
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Society of Human Genetics (ASHG), the American College of Medical Genetics and Genomics 
(ACMG) and the governmental regulators include the Food and Drug Administration (FDA) and 
the Government Accountability Office (GAO). The concerns raised by these organizations 
include the potential for consumer misinterpretation of test results and other misunderstandings 
as well as a misuse of health care resources, and a possibility of psychological harms54.  
 Misinterpretation of test results may result in unnecessary medical or other health-related 
decisions in the case of the perception of results to be higher risk than they actually may be and 
possible false reassurance in the case of the perception of results to be lower risk than they 
actually may be54. The possibility for misinterpretation is one of the reasons that test results are 
currently delivered via a trained professional (i.e. a genetic counselor or a physician).  
2.5 IMPORTANCE OF GENETIC COUNSELING 
It has been recommended by the American Society of Clinical Oncology (ASCO) and certain 
advocacy groups such as Facing Our Risk of Cancer Empowered (FORCE) that genetic testing 
for hereditary cancer syndromes take place in a setting with informed consent and with 
professional genetic counseling both pre- and post-genetic testing31. These recommendations 
have been due to the complexities that are involved in interpreting results in the context of the 
patient’s personal and family history of cancer6. Many of the research studies regarding 
outcomes of genetic testing, such as psychosocial implications and patient’s medical 
management decisions following testing, have taken place in the context of genetic counseling.  
 In 2015, Armstrong et al.55, published a study on the utilization and outcomes of BRCA 
testing and counseling and found that “individuals who received genetic counseling from a GC 
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demonstrated higher BRCA testing knowledge scores and expressed greater self-reported 
understanding of the information they received prior to testing.” It was also found that the 
patients who received genetic counseling from a genetic counselor were more satisfied in all 
measured categories compared to all other clinicians55 including “explained things clearly,” 
“listened to what I had to say,” “used language I understood,” “provided new information,” 
“really understood my concerns,” “cares for me,” “lessened my worries,” and “helped me cope 
better.”  
2.6 PSYCHOSOCIAL IMPLICATIONS AND MOTIVATIONS FOR GENETIC 
TESTING FOR CANCER RISK 
Psychosocial implications of genetic testing have been well studied and reported on in the 
literature. Pasacreta56 found motivations for genetic testing for hereditary breast and ovarian 
cancer (HBOC) included: (1) learning information about their children’s risk; (2) to inform 
decisions about how often cancer screening should take place and/or surgery would be an option; 
(3) to relieve uncertainty; (4) to inform life decisions; and (5) to gain information about HBOC 
for their own purposes and their families’. Reasons found for deciding to not undergo testing 
included fear of insurance discrimination and a possible personal inability to emotionally deal 
with the information that could be gained from genetic testing56. Wakefield et al.57 compared the 
attitudes towards genetic testing for cancer risk for HBOC compared to Lynch syndrome and 
reported the following findings: “(1) that there may be differences in the perceived benefits of 
genetic testing for individuals susceptible to different hereditary cancer syndromes; (2) affected 
individuals considering undergoing mutation search may not fully understand the implications of 
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receiving an inconclusive or ‘mutation not found’ result; (3) individuals considering genetic 
testing for cancer risk may be more concerned about the potential psychological impact of 
genetic testing than the evidence warrants, and last, (4) eliciting patients’ perceived pros and 
cons of testing can provide valuable information to improve individual patient care and the 
development of patient education materials.” 
 Specific to implications for population screening, a study was conducted using interviews 
and the analysis technique of grounded theory, of 14 female, asymptomatic carriers of BRCA1/2 
mutations, who belonged to families with a low prevalence of cancer. Shkedi-Rafid et al.58  
found that “(1) having no history of cancer in the immediate family was a source of optimism but 
also of confusion, (2) engaging in intensified medical surveillance and undergoing preventive 
procedures was preceived as health-promoting but also tended to induce a sense of physical and 
psychological vulnerability; and (3) there was overall support for BRCA pouplation screening, 
with some reservations.” 
2.7 AMAZON MECHANICAL TURKS 
Amazon Mechanical Turks (MTurk) is the dominant method of crowdsourcing used by 
researchers in the academic setting59. MTurk has recently become a popular source of research 
participants and has been used in this capacity for more than five years59. There is a growing 
body of literature both using MTurk as the participant sample and on the demographics and 
characteristics of the workers of MTurk. While workers of MTurk have been found to not be 
representative of the general population as a whole, they have been found to be more diverse 
than the typical samples used in research such as college students or community samples60,59.  
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When directly comparing studies using college student samples with MTurk samples, 
MTurk samples have been found to be more representative of the general population61. When 
MTurk samples are directly compared with other web-based probability samples, MTurk 
samples are less representative of the general population as a whole60,62,63. These comparisons 
with the general population are in terms of income, race, gender, and marital status.  
2.7.1 Demographics of MTurk 
The demographic characteristics of the MTurk population have been studied and reported in the 
literature. Amazon states that they have more than 500,000 registered workers of MTurk. The 
workers primarily consist of individuals from the United States and from India, although 
individuals from any country can register and be a worker for MTurk59. Many researchers limit 
their sample to only workers from the United States.  
As a whole, workers tend to be better educated and above average in cognitive skills. 
They are generally younger than the population as a whole64,65. The workers also tend to be more 
liberal and less religious than the general population66. MTurk workers are more likely to 
identify as LGBTQ59. Asian-Americans and European-Americans are overrepresented in the 
MTurk workforce. African Americans and Hispanics are underrepresented in the MTurk 
workforce65. MTurk workers are more likely to be unemployed or underemployed and have 
lower personal incomes67. Workers are less likely to be married and less likely to own their own 
home67,60. However, the workers are only slightly less likely to have biological children, and may 
be more likely to have stepchildren67. There have been inconsistent findings regarding the mental 
health, specifically of the presence depression and anxiety in MTurk workers67,68.  
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3.0  MATERIALS AND METHODS 
3.1 DESIGN AND RATIONALE 
The survey was designed through collaboration with several faculty members in the Graduate 
School of Public Health. There are four primary sections of the survey: initial interest level, six 
result scenarios, post-survey interest level and ordering preference, and demographics. Questions 
were specifically designed to elicit information relating to the interest level of the participants, 
their motivations for wanting testing or not, and some possible psychosocial effects.  
This study was made available to participants via a survey link on the Human Intelligence 
Task (HIT) created for Amazon Mechanical Turk workers on March 9th, 2016. The survey was 
closed on March 11th, 2016. The survey was revised multiple times by members of this 
committee and others in the Department of Human Genetics. A pilot study was conducted with 
respondents from the University of Northern Iowa, the University of Pittsburgh, and Amazon 
Mechanical Turk workers.  
Approval was obtained from the Institution Review Board at the University of Pittsburgh, 
IRB Approval #PRO14100612 (Appendix A).  
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3.1.1 Pilot Study 
The pilot study for this survey was conducted using two different cohorts. The first cohort 
consisted of individuals from the University of Northern Iowa and the University of Pittsburgh 
with active recruitment and participation occurring between April 20, 2015 and May 30, 2015. A 
total of 320 respondents were eligible (18 or older) and answered at least one question in the 
survey. The second cohort consisted of workers from Amazon Mechanical Turks, with active 
recruitment and participation occurring between July 29, 2015 and August 21, 2015. A total of 
413 respondents were eligible and answered at least one question in the survey.  
 This study was not originally intended to be a pilot study, but after significant analysis of 
parts of the study, issues with the survey design were revealed. Some of these issues included 
possible international responses from the Amazon Mechanical Turks, insufficient demographic 
questions, and unnecessary questions. In the subsequent study, these were corrected and other 
wording edits were made as well as the addition of a few questions.  
3.1.2 Survey Design 
The survey began with an eligibility question to ensure the participants were 18 years or older. 
Any participant who was not over the age of 18 was directed to a “thank you” page at the end of 
the survey. The first question of the survey assessed initial interest in a genetic test that could 
identify a hereditary risk of cancer. Very little background was given before this question about 
the test itself or possible results. The purpose of asking this question without very much 
information was to have the ability to compare initial gut-level interest before the participant 
really thought through what this test may or may not mean for them. This may be similar to a 
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physician or other healthcare professional simply asking someone if they would like to take this 
test without explaining implications of such a test. This may also be similar to a direct-to-
consumer company allowing an individual to simply sign up and send in a saliva sample for a 
genetic test like this without going through certain steps of explanation and informed consent. 
After the initial question to determine interest in genetic testing for hereditary cancer risk, there 
was a portion of the survey that involved the participant answering several questions related to 
six different possible scenarios in the context of genetic testing (Appendix B). 
 A total of six scenarios were created and presented to participants after asking the initial 
level of interest question. These six scenarios were possible test results that one could receive 
after going through genetic testing. The first three scenarios were risk scenarios, and in each 
case, the individual in the scenario tested positive for a mutation in a specific gene that had a 
certain level of risk for cancer associated with it. The three risk levels were modeled on possible 
cancer risks with a mutation in a low-risk gene (<25%), a moderate-risk gene (25-49%), or a 
high-risk gene (50% or higher). The fourth and fifth scenario were both negative results, with the 
fifth scenario involving a diagnosis of cancer 15 years after receiving a negative result for this 
genetic test. The last scenario was a result of a variant of uncertain significance (VUS), where a 
change in the DNA was found, but the lab is unsure if that is a pathogenic, harmful mutation or a 
benign polymorphism. The purpose of having the participant go through each scenario was to 
have the participant more fully understand the possible results of genetic testing and to have 
them think through how these results may or may not affect different aspects of their lives.  
 The last portion of the survey before the demographics questions was the same question 
asked at the beginning of the survey. This was asked to demonstrate whether there was a 
difference in interest level after participants learned more about the testing and possible impacts. 
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Participants still interested in testing were then asked how they would prefer to have this testing 
coordinated, whether they would want to take this test directly from a testing lab (direct-to-
consumer), coordinated by their primary care physician, or through a genetic counselor.  
 The survey concluded with questions relating to the demographics of the participants. 
Some of the demographic questions were based off of questions asked by census surveys. Other 
demographic questions were asked based on hypotheses of what personal factors may influence 
answers to the survey questions. These demographic questions included sex, age, significant 
family history of cancer, personal history of cancer, experience having had genetic testing, 
ranking of their knowledge/understanding of genetics, level of education, race/ethnicity, past or 
current employment in healthcare, income level, marital status, political views, level of 
religiosity, military service, and current region of residence in the United States.  
3.2 AMAZON MECHANICAL TURKS PAYMENT AND SETTINGS 
Amazon Mechanical Turks was selected as the source of participants because of the vast amount 
of research on this group that has been reported on in the literature as well as out of convenience. 
As a Requester, an account is set up from which the workers are paid a set amount for 
completing a “Human Intelligence Task” (HIT). An account was set up using the study email, 
pscstudy@pitt.edu, and $600 was deposited into the account via a WePay debit card. Each 
MTurk worker was paid $0.50 if he/she entered the correct code into the “submission” box. The 
fees collected by Amazon Mechanical Turks as a company were $0.20 per submission. The title 
of the HIT was “Survey about Opinions on Genetic Testing” and a link was provided once the 
worker accepted the HIT that took them to the Qualtrics survey.  
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 Certain settings were used in our survey post on the Amazon Mechanical Turks. The first 
setting selected was not requiring the workers to be “Masters.” MTurk Masters are those who 
have been identified by MTurk as high performing and have “demonstrated excellence across a 
wide range of HITs” as is stated on the website, and these workers must continue to pass the 
statistical monitoring to maintain this status. Requiring workers to be “Masters” could have 
created a bias in our sample, which was not desired. This HIT was limited to those workers 
located in the United States. Only workers who qualified for this HIT were able to view the HIT 
in order to eliminate the possibility of international responses. 
3.3 DATA ANALYSIS 
All data were recorded using respondent ID’s by the Qualtrics Survey System through the 
University of Pittsburgh, insuring the participants’ anonymity. The Qualtrics survey system was 
used to compile reports of the data, which were exported to Microsoft Excel. This excel 
spreadsheet of all of the compiled data was then imported into SPSS Statistics. SPSS was used to 
analyze the quantitative data. For this analysis, p-values of 0.050 or less were considered to be 
statistically significant. 
3.3.1 Quantitative Analysis of Interest Level 
Either Qualtrics Survey System or the data that had been imported into SPSS was used to 
analyze each demographic category of the respondents. Qualtrics Survey System automatically 
calculated Chi-squared tests and these tests were used for demographics where only 2 groups 
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were present (e.g. sex, significant family history of cancer, etc.). SPSS software was used to 
calculate one-way ANOVA tests were used for demographics with 3 or more groups present (e.g. 
race, level of education, age etc.). For the statistically significant demographics, percentages of 
respondents for each answer choice was calculated and stated. 
3.3.2 Likert-Scale Psychosocial Questions 
Each scenario of the survey had multiple statements that the participants were asked to rank 
agreement/disagreement with using a likert scale. The likert scale rankings used were; Strongly 
Disagree, Disagree, Neither Agree nor Disagree, Agree, and Strongly Agree. Each of these 5 
rankings were coded 1 through 5 respectively to quantitatively assess the answers and 
differences between groups if present. Independent sample, 2-tailed t-tests were used to identify 
significant differences between demographic groups where only 2 groups exist (i.e. sex). One-
way ANOVA tests were used to identify significant differences between demographic groups 
where 3 or more groups exist (i.e. political views). Statements were made in section 4.4 
regarding significant differences between groups in each demographic. Means of each group in 
the demographic were used to make such statements such as “those of ___________ were the 
most likely to agree/strongly agree with ___________.”  
3.3.3 Thematic Analysis 
Thematic analysis was used to identify themes in the qualitative questions. Thematic analysis is 
used to encode qualitative data and identify themes and patterns within it. Thematic analysis is a 
widely-used approach to analyzing qualitative information and there are various approaches that 
 28 
have been reported in the literature69. The approach utilized in this study was a step-by-step 
process developed by Braun and Clarke70. The step-by-step process is listed in below70: 
 
1: Familiarizing yourself with your data 
2: Generating Initial Codes 
3: Searching for Themes 
4: Reviewing Themes 
5: Defining and Naming Themes 
6: Producing the Report 
 
All of the responses to the open-ended questions were read thoroughly at least twice 
before beginning the coding process in order to become familiar with the data (Step 1). 
Preliminary notes with possible coding terms were recorded (Step 2) and from there common, 
major themes were identified (Step 3). Usually thematic analysis is performed on more robust 
qualitative data such as interviews or focus groups. Since this data is not as robust, and most 
responses are limited to a few words to a sentence, many of the initial codes either became 
themes or were grouped to fit a broader theme (Step 4/5). The thematic analysis performed was 
inductive and data-driven as themes were not pre-set but rather emerged after the responses were 
read and preliminarily analyzed.  
Participants’ answers to these questions were divided by question into separate Microsoft 
Excel files. These excel tables were then imported into Microsoft Word. The highlighting tool 
was used in Microsoft Word to highlight the identified themes. The number of participants’ 
whose response fit into a certain theme was quantified using percentages and used to draw 
conclusions. 
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4.0  RESULTS 
4.1 SURVEY COMPLETION RATE 
One thousand and forty-six Amazon Turk workers clicked on the survey link and responded to 
the eligibility question of the survey. One of these workers was not eligible to participate in this 
research study because he or she was not 18 years of age. Of those workers eligible, one 
thousand and forty workers responded to at least one question of the survey and eight hundred 
and sixty-one workers fully completed the survey. This gives a survey completion rate of 82.8% 
(861/1040).  
4.2 DEMOGRAPHICS 
Table 1 illustrates the specific breakdown of the respondent characteristics. Participants ranged 
in age from 18 – 83 years old with the majority being between the ages of 25-39 (52.96%). More 
females (55.75%) participated in the survey than males (44.25%). The majority of participants 
had a post-high school education, with approximately 16% having a graduate or professional 
degree, 38% having a bachelor degree, 10% having an associate degree, and 27% having some 
college, but no degree. The majority of the participants were white (80.95%). 
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The number of married (41.93%) and never-married (43.90%) participants were similar 
and made up the bulk of respondents. The majority of respondents reported that they have not 
ever served in the military (93.96%). The majority of participants have never been employed in 
healthcare (79.67%).  
Respondents were from various regions of the United States. The largest portion of 
respondents lived in the Southeast (25.44%). The largest portion of respondents had liberal 
political views (45.41%). 
When asked if they had a significant family history of cancer, 543 (63.07%) participants 
reported that they did not have a significant family history of cancer. Of the 861 respondents, 35 
(4.07%) had personally had cancer. Forty-eight (5.57%) respondents had had some sort of 
genetic testing in the past. 
The respondents were asked to rank their knowledge and understanding of genetics. 
Fifty-three (6.16%) respondents ranked their knowledge/understanding of genetics as ‘excellent,’ 
282 (32.75%) ranked their knowledge/understanding of genetics as ‘good,’ 441 (51.22%) ranked 
their knowledge/understanding of genetics as ‘average,’ and 85 (9.87%) ranked their 









Table 1: Demographics of Survey Respondents 




Sex Male 381 44.25 
Female 480 55.75 
Education <12th grade/no diploma 3 0.35 
High School or GED 72 8.36 
Some college/no degree 236 27.41 
Associate Degree 85 9.87 
Bachelor Degree 329 38.21 
Graduate/Professional Degree 136 15.80 
Age 18-24 111 12.89 
25-29 190 22.07 
30-39 266 30.89 
40-49 137 15.91 
50-59 97 11.27 
60-69 56 6.50 
70+ 4 0.46 
Race/Ethnicity White 697 80.95 
Black or African American 61 7.08 
Hispanic or Latino 39 4.53 
Asian 45 5.23 
Native Hawaiian or Pacific 
Islander 
2 0.23 
American Indian or Alaska 
Native 
4 0.46 
Other 13 1.51 
Household Income Level Less than $10,000 46 5.34 
$10,000 – 19,999 76 8.83 
$20,000 – 29,999 109 12.66 
$30,000 – 39,999 123 14.29 
$40,000 – 49,999 110 12.78 
$50,000 – 74,999 192 22.30 
$75,000 – 99,999 99 11.50 
$100,000 – 149,999 77 8.94 
$150,000 or more 29 3.37 
Marital Status Married 361 41.93 
Never Married 378 43.90 
Widowed 14 1.63 
Divorced 82 9.52 
Separated 26 3.02 
Military Service Yes 52 6.04 






Table 1 continued: 
Region of the US currently living in Northeast (PA, MD, DE, NJ, 
CT, RI, MA, NH, ME, VT, 
NY, DC) 
159 18.47 
Southeast (WV, VA, NC, 
SC, GA, FL, AL, MS, LA, 
AR, TN, KY) 
219 25.44 
Midwest (OH, MI, IN, IL, 
WI, MN, IA, MO, ND, SD, 
NE, KS) 
200 23.23 
Southwest (OK, TX, NM, 
AZ) 
106 12.31 
West (WA, OR, ID, MT, 
WY, CO, UT, NV, CA) 
173 20.09 
Alaska or Hawaii 2 0.23 
US Territory (American 
Samoa, Guam, Northern 
Mariana Islands, Puerto 
Rico, US Virgin Islands) 
2 0.23 
Political Views Liberal 391 45.41 
Moderate 265 30.78 
Conservative 205 23.81 
Work/have worked in healthcare Yes 175 20.33 
No 686 79.67 
Have had genetic testing Yes 48 5.57 
No 813 94.43 
Significant Family History of Cancer Yes 318 36.93 
No 543 63.07 
Personal History of Cancer Yes 35 4.07 
No 826 95.93 
Ranking Knowledge of Genetics Excellent 53 6.16 
Good 282 32.75 
Average 441 51.22 
Poor 85 9.87 
“Religion is an important part of my life” (likert 
scale) 
Strongly Disagree 322 37.40 
Disagree 105 12.20 
Neither Agree nor Disagree 91 10.57 
Agree 203 23.58 
Strongly Agree 140 16.26 
 
 33 
4.3 INTEREST LEVEL IN TAKING A GENETIC TEST FOR HEREDITARY 
CANCER 
Study participants were asked if they would be interested in a genetic test that tests the known 
cancer genes both at the beginning of the survey and after the scenario portion of the survey at 
the end. The three possible options for this question were that the participant would take the test 
immediately if it were possible, they would consider taking this test in the future, or that they 
would never take a test like this. Table 2 and Figure 2 illustrate the participants’ responses to this 
question, at the beginning and the end of the survey.  
4.3.1 Initial Interest Level 
At the beginning of the survey, the majority of respondents were interested in taking a 
cancer genetic test immediately (71.44%, n = 1040). Two hundred and thirty respondents 
(22.11%) were not currently interested, but would consider it later in life and 67 respondents 
(6.44%) would never take this genetic test. 
Differences in initial interest in taking a genetic test for hereditary cancer risk existed 
between several demographic groups. Those with a significant family history of cancer were 
more likely (p-value = <0.001) to be interested in taking a test like this immediately (80.50%, 
n=318) compared to those without a significant family history of cancer (68.69%, n=543). 
Respondents who ranked their knowledge/understanding of genetics as “good” were significantly 
(p-value = 0.029) more likely (79.79%, n = 282) to be interested in taking this test immediately 
compared to those ranked their knowledge/understanding of genetics as “excellent” (67.92%, n = 
53), “average” (70.30%, 441), and “poor” (68.24%, n = 85).  
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There were not statistically significant differences found in the following demographics: 
sex, genetic testing experience, personal history of cancer, military service, education level, 
race/ethnicity, income level, healthcare employment, marital status, level of religiosity, political 
views, or geographic region.  
4.3.1.1 Themes identified for those interested immediately 
Those participants who answered “Yes, I would take that test today if I could” to the initial 
question of interest, were asked “why would you want to take a test like this?” The major themes 
identified in the participants’ responses to this question were: 1) knowledge or curiosity; 2) 
precaution/preventative measures/preparation; 3) clarifying personal cancer risks; 4) experiences 
with cancer (family history or personal experience); 5) children or future generations.  The 
prevalence of each of these themes was calculated (Table 2). Specific examples of themes from 
participant quotes are shown in Table 3. 
Table 2: Themes identified in those Immediately Interested 
Theme n (%), n = 734 
Knowledge or Curiosity 439 (59.81) 
Precaution/preventative measures/preparation 285 (38.83) 
Clarifying Personal Cancer Risks 185 (25.20) 
Experiences with Cancer 112 (15.26) 





Table 3: Participant Quotes 
Theme Quote 
Knowledge or Curiosity “I would want to take a test like this because of curiosity.” 
Precaution/preventative 
measures/preparation 
“To help me watch for potential warning signs of cancer that I’m 
predisposed to so that I could get diagnosed early.” 
Cancer Risks “In order to know if I have increased risk of cancer” 
Experiences with 
Cancer 
“Because my father died of multiple myeloma and my uncle died of 
colon cancer. I would like to know whether I have the gene for either 
of these diseases.” 
Children or future 
generations 
“I would want to know to prepare for later in life and to avoid passing 
it to my future children.” 
 
4.3.1.2 Themes identified for those possibly interested in the future 
Participants who answered “currently not interested, but would consider it later in life” to the 
initial question of interest in this genetic test, were asked “why would you consider taking this 
test in the future?” A total of 227/1025 (22.15%) respondents answered this question and themes 
were identified. Some of these major themes are the same as major themes identified in those 
wanting to immediately take this test. The themes identified were: 1) knowledge or curiosity; 2) 
precaution/preventative measures/preparation; 3) would like the option in the future/when older; 
4) Psychological effects/anxiety; 5) Give research time to advance/“bugs” worked out; and 6) If 
things change/new family members get diagnosed. Prevalence of the major themes identified are 








Table 4: Themes identified in Individuals currently not interested in testing, but may be in 
the future 
 
Theme n (%), n = 227 
Knowledge or Curiosity 49 (21.59) 
Precaution/preventative measures/preparation 48 (21.15) 
Would like the option in the future/when 
older 
52 (22.91) 
Psychological effects/anxiety 14 (6.17) 
Give research time to advance/”bugs” worked 
out 
9 (3.96) 





Table 5: Participant Quotes 
Theme Quote 
Knowledge or Curiosity “Curiosity, not that I care much.” 
Precaution/preventative 
measures/prepare 
“Just so I might be prepared for what might be coming.” 
Would like the option 
in the future/when older 




“I am not mentally prepared to take it now, but I would take it later 
since I’ve had family members with cancer” 
Give research time to 
advance/”bugs” worked 
out 
“It would give time for any ‘bugs’ to be worked out of it (i.e. false 
postives), and it may be something useful in the future as far as taking 
possible preventative measures that I might not otherwise take.” 
If things change/new 
family members 
diagnosed 
“If I had a reason to believe it was a good idea, such as other family 
members developing cancer that could be hereditary.” 
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4.3.1.3 Themes identified for those not interested 
Participants who answered “no, I would never take a test like that” to the initial question of 
interest in this genetic test, were asked “why would you never take a test like this?” A total of 
64/1025 (6.24%) respondents answered this question and major themes were identified. The 
major themes identified were: 1) conspiracy theory/distrust; 2) psychological stress/anxiety; and 
3) inevitability (cannot change anything); 4) age; and 5) no interest. Prevalence of the major 
themes identified are depicted in Table 6 and example quotes are illustrated in Table 7.  
Table 6: Themes from Individuals not Interested in Testing 
Theme n (%), n = 64 
Conspiracy Theory/Distrust of the test 8 (12.50) 
Psychological Stress/Anxiety 22 (34.38) 
Inevitability (cannot change anything) 9 (14.06) 
Age 5 (7.81) 
No Interest 11 (17.19) 
 
Table 7: Participant Quotes for those Not Interested in Testing 
Theme Quote 
Conspiracy Theory/Distrust of the test “All genetic testing has the possibility of 
government data collection and misuse” 
Psychological Stress/Anxiety “For me personally, it would cause a great deal 
of stress and worrying.” 
Inevitability (cannot change anything) “I do not wish to know something like that, since 
I can’t do anything about it anyway and it would 
make me feel anxious and depressed.” 
Age “I’m old and I have no children. If I get a 
hereditary cancer then so be it.” 
No Interest “There is no history of cancer in my family and I 
really just don’t have any interest in taking a test 
like this.” 
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4.3.2 Interest Level after the Result Scenarios 
By the end of the survey, fewer participants were interested in taking a cancer genetic test 
immediately (64.92%), more participants were currently not interested but would consider taking 
it later in life (26.84%), and more participants decided they would never take a test like this 
(9.64%). 
Analyzing the demographic differences for the respondents’ answers to the interest level 
question after the scenario portion of the survey, those with a significant family history of cancer 
were significantly more likely (p-value = <0.001) to be interested in taking a test like this 
immediately (74.53%, n=318) compared to those without a significant family history of cancer 
(59.30%, n=543). Those who had previously undergone some sort of genetic testing were more 
likely (p-value = <0.001) to be interested in taking a test like this immediately (81.25%, n = 48) 
compared to those who have not had genetic testing (63.96%, n = 813). Respondents who ranked 
their knowledge/understanding of genetics as “good” were significantly (p-value = 0.004) more 
likely (70.92%, n = 282) to be interested in taking this test immediately and those who ranked 
their knowledge as “poor” were significantly less likely be interested in taking this test 
immediately (51.76%, n = 44) thank those who ranked their knowledge as “excellent” (60.37%, 
n = 53) or “average” (64.17%, n = 441). Those without current or past employment in healthcare 
were significantly (p-value = 0.020) more likely to be interested in taking this test immediately. 
There were not statistically significant differences found in the following demographics: 
sex, personal history of cancer, military service, education level, race/ethnicity, income level, 
marital status, level of religiosity, political views, or geographic region.  
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4.3.3 Comparison of Interest Level Before/After Scenarios 
Table 8 and Figure 2 illustrate the participants’ responses to this question, at the beginning and 
the end of the survey. 
 
Table 8: Participant Interest; before/after the survey 
  Interest at the end of the survey  
  Yes, today 
Currently 
no, consider 
later in life 
Never Total: 
Interest at the 
beginning of 
the survey 
Yes, today 520 86 23 629 
Currently 
no, consider 
later in life 
39 124 17 180 
Never 0 9 43 52 






Percentage of Participants Interested in Testing; Before/After 
 
A total of 109 (17.33%) participants who had initially wanted to take this test today if 
they could, reconsidered after going through the scenario portion of the survey. Of the 629 
participants who answered in the beginning of the survey that they would be interested in taking 
this test immediately, 86 (13.67%) participants decided by the end of the survey that they were 
actually not currently interested, but would consider it later in life and 23 (3.66%) participants 
decided by the end of the survey that they actually would never take a test like this. A total of 
109 (17.33%) participants who had initially wanted to take this test today if they could, 







Yes, Today Maybe Later No, Never
Interest in Genetic Testing for 










Of the 180 participants who answered in the beginning of the survey that they were 
currently not interested, but would consider taking it later in life, 39 (21.67%) decided by the end 
of the survey that they would actually take this test today if they could, and 17 (9.44%) decided 
by the end of the survey that they would never take a test like this.  
For the 52 participants who originally answered that they would never take a test like 
this, 9 (17.31%) of them decided that they were currently not interested, but would consider it 
later in life. There were no participants who answered that they would never take a test like this 
in the beginning of the survey who had decided at the end of the survey that they would take this 
test today if they could. 
The interest of those who answered that they had a significant family history of cancer 
differed from those who did not have a significant family history of cancer. The observed 
differences between groups occurred for the demographics of: family history of cancer, previous 
experience with genetic testing, knowledge/understanding of genetics, and employment in 
healthcare. It is also interesting to note that those who had previously had genetic testing 
responded exactly the same to the interest level question in both the beginning of the survey and 
at the end of the survey. 
There was not a statistically significant difference found between individuals who have 
worked in healthcare and those who have not for the interest question asked at the beginning of 
the survey, however, there was a difference between these groups that was found to be 
statistically significant for the interest question at the end of the survey. 
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4.4 POSSIBLE RESULT SCENARIOS  
Each scenario was designed to be a possible result of genetic testing in the context of population 
screening. For each scenario, participants were asked to indicate the degree to which they agreed 
or disagreed with certain statements. They were then asked 3 open-ended questions to allow the 
participants to elaborate more on their feelings and thought processes related to these scenarios. 
These questions were designed to encourage the participants to process more about how genetic 
testing may impact different parts of their lives given possible results. The statistically significant 
results are described. As some of these demographic groups are quite small, there is also a 
possibility that there are significant differences between other groups that were not detected by t-
tests or ANOVA because there is not sufficient power. 
When comparing the demographics in the scenarios, it is important to note that there may 
be significant demographic differences between groups that were not found to be statistically 
significant in our survey because there may not have been enough power to find statistically 







4.4.1 Scenario 1 
SCENARIO: You go through comprehensive genetic testing for cancer genes and are found 
to have a changed gene that is harmful and increases your risk of a certain type cancer (for 
example, colon cancer) to 50%. This would mean that over the course of your lifetime, 
there is a 1 in 2 chance that you would develop that certain type of cancer. 
 
Table 9 illustrates the results from this scenario. In this first scenario, 63.36% (n = 958) 
of respondents agreed or strongly agreed with the statement, “this test result would affect my 
everyday life.” More than half of respondents (56.47%, n = 958) answered either “agree” or 
“strongly agree” to the statement, “this test result would affect my mental health.” The majority 
of participants (56.99%, n = 958) disagreed or strongly disagreed with the statement “this test 
result would impact my ability to find a partner (assuming you did not have a partner at the 
time).” The majority of participants (70.67%, n = 958) did not feel that this test result would 
impact their employment, disagreeing with the statement “this result would impact my ability to 
find and/or keep a job.” More participants agreed or strongly agreed (45.82%, n = 958) with the 
statement “this test result would impact my decision on whether or not to have children (each 
child would have a 50% chance of inheriting the harmful gene from you).” The majority of 
participants (66.81%, n = 958) agreed or strongly agreed with the statement “I would talk to my 
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4.4.1.1  Comparison of Demographics for Scenario 1 
T-tests or one-way ANOVA statistical tests were performed where appropriate to determine if 
there were any groups that were statistically significantly different from each other. Table 10 









Table 10: Scenario 1 Statistically Significant Differences in Demographic Groups 
 
 Those without a family history of cancer were more likely (p-value = 0.033) to agree or 
strongly agree that this test result would affect the ability to find a partner. Those who had not 
had genetic testing were more likely (p-value = 0.023) to agree or strongly agree that this test 
Statement Demographic p-value 
This test result would affect my everyday 
life. 
Military Service 0.014 
This test result would affect my mental 
health. 
Sex 0.023 
Rank Knowledge 0.020 
This test result would impact my ability to 
find a partner. 
Sex 0.001 
Family History of Cancer 0.033 
Rank Knowledge 0.034 
Education Level 0.013 
Income Level 0.008 
Race/Ethnicity 0.013 
This test result would impact my ability to 
find and/or keep a job. 
Sex <0.001 
Education Level 0.002 
Income Level <0.001 
Race/Ethnicity 0.003 
This test result would impact my decision 
on whether or not to have children. 
Genetic Testing Experience 0.023 
Marital Status 0.029 
Political Views 0.015 
I would talk to my family about this gene 
and my test result 
Marital Status 0.050 
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result would affect the decision on whether to have children or not. Those who had never served 
in the military were more likely (p-value = 0.014) to agree or strongly agree that this test result 
would impact their everyday life. 
 Those with an “excellent” knowledge/understanding of genetics were significantly more 
likely (p-value = 0.034) to disagree/strongly disagree that this test result would impact their 
ability to find a partner. Those with a “poor” knowledge/understanding of genetics were 
significantly more likely (p-value = 0.020) to agree/strongly agree that this test result would 
affect their mental health. Females were more likely (p-value = 0.023) to agree or strongly agree 
that their mental health would be affected with this test result. Men were more likely (p-value = 
0.001) to agree or strongly agree that this test result would affect their ability to find a partner 
and were also more likely (p-value = <0.001) to agree or strongly agree that this test result would 
affect their ability to find and/or keep a job.  
Those with some college/no degree were significantly more likely (p-value = 0.013) to 
disagree/strongly disagree that this test result would affect their ability to find a partner and those 
with less than a 12th grade education were significantly more likely (p-value = 0.002) to 
agree/strongly agree that this test result would affect their ability to find/keep a job. Those with 
an income level of $150,000+ were significantly more likely (p-value = 0.008) to 
disagree/strongly disagree that this test result would affect their ability to find a partner and also 
significantly more likely (p-value = <0.001) to disagree/strongly disagree that this test result 
would affect their ability to find/keep a job. Those of Asian ethnicity were significantly more 
likely to disagree/strongly disagree (p-value = 0.013) that this test result would affect their ability 
to find a partner but were significantly more likely to agree/strongly agree (p-value = 0.003) that 
this test result would affect their ability to find/keep a job than other ethnicity groups were. 
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Those who were separated (marital status) were the most likely (p-value = 0.029) to 
agree/strongly agree that this test result would have an impact on child-bearing decisions and 
those who were widowed were the least likely (p-value = 0.050) to agree/strongly agree that they 
would discuss this gene/test result with their family. Political views had a statistically significant 
impact on whether this test result would impact the decision to have children or not and those 
who were conservative (p-value = 0.015) were the most likely to disagree/strongly disagree that 
this test result would have an impact on the decision to have children or not.  
 The t-tests performed did not show any statistically significant differences dependent on a 
personal history of cancer. The one-way ANOVA tests did not show any statistically significant 
differences between level of religiosity or for the region of the United States that the participants 
were located in. 
4.4.2 Scenario 2 
SCENARIO: You go through comprehensive genetic testing for cancer genes and are found 
to have a broken gene that increases your risk of a certain type of cancer (for example, 
colon cancer) to 80%. This would mean that over the course of your lifetime, there is a 4 in 
5 chance of developing that type of cancer. 
 
Table 11 illustrates the results from this scenario. In this scenario, the majority of 
participants indicated that this test result would affect their everyday life (78.17%, n = 907), and 
affect their mental health (74.75%, n = 907). Similar numbers of participants indicated that this 
test result would impact their ability to find a partner (39.47%, n = 907) as those that indicated 
that this would not impact their ability to find a partner (39.36%, n = 907). Most participants 
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indicated that this test result would not impact their ability to find and/or keep a job (53.14%, n = 
907). Most participants indicated that this test result would impact the decision to have children 
(62.08%, n = 907). The vast majority of participants indicated that they would talk about the 
gene and test result with their family (90.07%, n = 907).  
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4.4.2.1 Comparison of Demographics for Scenario 2 
Table 12 shows the statistically significant differences between demographic groups for the 
second scenario. 
 
Table 12: Scenario 2 Statistically Significant Differences in Demographic Groups 
Statement Demographic p-value 
This test result would affect 
my everyday life. Sex 0.004 
This test result would affect 
my mental health. 
Sex <0.001 
Marital Status 0.018 
Political Views 0.034 
This test result would impact 
my ability to find a partner. (none)  
This test result would impact 
my ability to find and/or keep 
a job. 
Education Level 0.039 
Income Level 0.007 
This test result would impact 
my decision on whether or 
not to have children. 
Marital Status 0.029 
Political Views 0.041 
I would talk to my family 
about this gene and my test 
result 
Family History of Cancer <0.001 
Marital Status <0.001 
 
Females were more likely to agree or strongly that their everyday life (p-value = 0.004) 
and mental health (p-value = <0.001) would be affected with this test result. Those with a 
significant family history of cancer were more likely (p-value = <0.001) to indicate that they 
would talk about this gene/test result with their family members. Those whose highest level of 
education was high school/GED or lower were significantly more likely (p-value = 0.039) to 
agree/strongly agree that this test result would affect their ability to find/keep a job.  
The participants whose household income level was less than $10,000 were significantly 
more likely (p-value = 0.007) to agree/strongly agree that this test result would affect their ability 
to find/keep a job. Those who were widowed or divorced were significantly less likely (p-value = 
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0.029) to agree/strongly disagree that this test result would impact their decision to have kids. 
Those who were never married were the most likely (p-value = 0.018) to agree/strongly agree 
that this test result would affect their mental health. Those who were widowed were significantly 
less likely (p-value = <0.001) to agree/disagree that they would discuss this test result with their 
family. Those who were liberal were significantly more likely (p-value = 0.041) to 
agree/strongly agree that this test result would impact their decision to have children compared 
with those who were moderate or conservative. Those who were liberal were also significantly 
more likely (p-value = 0.034) to agree/strongly agree that this test result would affect mental 
health.  
 Statistically significant differences for the demographics of personal history of cancer, 
previous genetic testing experience, military service, knowledge/understanding of genetics, level 
of religiosity, and what region of the United States they reside in were not found for this 
scenario.  
4.4.3 Scenario 3 
SCENARIO: You go through comprehensive genetic testing for cancer genes and are found 
to have a broken gene that increases your risk for a certain type of cancer to 15-25%. This 
would mean that over the course of your lifetime there is approximately a 1 in 5 chance of 
developing that type of cancer. 
 
Table 11 illustrates the full results from the likert-scale questions in this scenario. In this 
first scenario, 50.67% (n = 884) of respondents disagreed or strongly disagreed with the 
statement, “this test result would affect my everyday life.” More than half of respondents 
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(69.12%, n = 884) answered either “agree” agree or strongly agree” to the statement, “this test 
result would affect my mental health.” The majority of participants (75.79%, n = 884) disagreed 
or strongly disagreed with the statement “this test result would impact my ability to find a partner 
(assuming you did not have a partner at the time).” The majority of participants (81.23%, n = 
884) did not feel that this test result would impact their employment, disagreeing with the 
statement “this result would impact my ability to find and/or keep a job.” More participants 
disagreed or strongly disagreed (59.61%, n = 884) with the statement “this test result would 
impact my decision on whether or not to have children (each child would have a 50% chance of 
inheriting the harmful gene from you).” The majority of participants (69.12%, n = 884) agreed or 
strongly agreed with the statement “I would talk to my family about this gene and my test 
result.” 
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4.4.3.1 Comparison of Demographics for Scenario 3 
Table 14 illustrates statistically significant findings in demographic differences for the third 
scenario. 
 
Table 14: Scenario 3 Statistically Significant Differences in Demographic Groups 
Statement Demographic p-value 
This test result would affect 
my everyday life. 
Sex 0.044 
Race/Ethnicity 0.015 
This test result would affect 
my mental health. Race/Ethnicity 0.030 
This test result would impact 
my ability to find a partner. 
Sex 0.027 
Education Level 0.001 
Race/Ethnicity 0.001 
Income Level <0.001 
Region of Residence 0.003 
This test result would impact 
my ability to find and/or keep 
a job. 
Education Level 0.003 
Race/Ethnicity 0.005 
Income Level <0.001 
Region of Residence 0.004 
This test result would impact 
my decision on whether or 
not to have children. 
Education Level 0.008 
Race/Ethnicity 0.047 
I would talk to my family 
about this gene and my test 
result 
Family History of Cancer <0.001 
Marital Status 0.001 
Level of Religiosity 0.024 
Genetic Testing Experience 0.009 
 
 Those with a significant family history of cancer were more likely (p-value = <0.001) to 
indicate that they would talk about this gene/test result with their family members. Those who 
had never had genetic testing were less likely (p-value = 0.009) to indicate that they would talk 
about this gene/test result with their family members. Those with some college/no degree were 
the most likely (p-value = 0.001) to disagree/strongly disagree that this result would impact their 
ability to find a partner as well as the most likely (p-value = 0.003) to disagree/strongly disagree 
that this result would impact their ability to find/keep a job. Those with a Bachelor degree were 
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the most likely (p-value = 0.008) to disagree/strongly disagree that this result would impact their 
decision to have children or not. Those with an income of $100,000 - $149,999 were found to be 
the most likely (p-value = <0.001) to disagree/strongly disagree that this test result would affect 
their ability to find a partner as well as the most likely (p-value = <0.001) to disagree/strongly 
disagree that this test result would affect their ability to find/keep a job.  
Those who were married were the most likely (p-value = 0.001) to agree/strongly agree 
that they would discuss this gene and test result with their family. Those who strongly agreed 
with the statement “religion is an important part of my life” were the most likely (p-value = 
0.024) to agree/strongly agree that they would talk to their family about this gene and test result. 
The region of the United States that the participant currently resides in was found to be 
statistically for the ability to find a partner (p-value = 0.003) and the ability to find or keep a job 
(p-value = 0.004). There were only 2 participants from Alaska or Hawaii and only 2 participants 
from a US Territory. The participants from Alaska or Hawaii were significantly more likely to 
disagree/strongly disagree that this would impact their ability to find a partner where the 
participants from a US Territory were significantly more likely to agree/strongly agree that this 
would impact their ability to find a partner. The other regions, all from the continental US, were 
much more similar and due to the small sample size from Alaska/Hawaii or the US Territories, 
these differences may not be found in a more representative sample of those regions.  
 Those who were Hispanic or Latino were the most likely (p-value = 0.001) to 
disagree/strongly disagree that this result would impact their ability to find a partner, as well as 
the most likely (p-value = 0.005) to disagree/strongly disagree that this result would impact their 
ability to find/keep a job, the most likely (p-value = 0.047) to disagree/strongly disagree that this 
result would impact their decision to have children, and the most likely (p-value = 0.030) to 
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disagree/strongly disagree that this result would affect their mental health. Those of Asian 
ethnicity were the most likely (p-value = 0.015) to agree/strongly agree that this test result would 
affect their everyday life.  
 Statistically significant differences for the demographics of personal history of cancer, 
political views, military service, and levels of knowledge/understanding of genetics were not 
found for this scenario.  
4.4.4 Scenario 4 
Scenario: You go through comprehensive genetic testing for cancer genes and are found to 
have an uncertain result. This means that there was a change found in a gene that is 
associated with a certain cancer.  However, it is unclear whether that change is harmless, 
or if that change causes an increased risk for a certain type of cancer. 
 
Table 15 illustrates the full results from the likert-scale questions in this scenario. In this 
first scenario, 56.38% (n = 869) of respondents disagreed or strongly disagreed with the 
statement, “this test result would affect my everyday life.” More than half of respondents 
(51.78%, n = 869) answered either “disagree” or strongly disagree” to the statement, “this test 
result would affect my mental health.” The majority of participants (77.79%, n = 869) disagreed 
or strongly disagreed with the statement “this test result would impact my ability to find a partner 
(assuming you did not have a partner at the time).” The majority of participants (80.58%, n = 
869) did not feel that this test result would impact their employment, disagreeing with the 
statement “this result would impact my ability to find and/or keep a job.” More participants 
disagreed or strongly disagreed (67.21%, n = 869) with the statement “this test result would 
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impact my decision on whether or not to have children (each child would have a 50% chance of 
inheriting the harmful gene from you).” The majority of participants (55.70%, n = 869) agreed or 
strongly agreed with the statement “I would talk to my family about this gene and my test 
result.” 
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4.4.4.1 Comparison of Demographics for Scenario 4 
Table 16: Scenario 4 Statistically Significant Differences in Demographic Groups 
Statement Demographic p-value 
This test result would affect 
my everyday life. 
Race/Ethnicity 0.041 
Income 0.012 
Level of Religiosity 0.036 
This test result would affect 
my mental health. Genetic Testing Experience 0.004 
This test result would impact 
my ability to find a partner. 
Level of Education <0.001 
Race/Ethnicity 0.028 
Income 0.001 
Region of Residence 0.002 
This test result would impact 
my ability to find and/or keep 
a job. 
Level of Education 0.002 
Race/Ethnicity 0.028 
Income 0.001 
Level of Religiosity 0.021 
Region of Residence 0.003 
This test result would impact 
my decision on whether or 
not to have children. 
Level of Education 0.007 
Race/Ethnicity 0.006 
I would talk to my family 
about this gene and my test 
result 
Genetic Testing Experience 0.011 
Level of Religiosity 0.001 
 
Table 16 shows the statistically significant demographic differences between participants for 
Scenario 4. Those who had previously had genetic testing were more likely (p-value = 0.004) to 
state that this test result would affect their mental health and more likely to state that they would 
talk to their family about these test results (p-value = 0.011). Those with a High School/GED 
education or less were the least likely to disagree or strongly disagree that this VUS test result 
would affect their ability to find a partner (p-value = <0.001), affect their ability to find/keep a 
job (p-value = 0.002), and impact their decision about having children (p-value = 0.007).  
Those of Hispanic or Latino ethnicity were the most likely to disagree/strongly disagree 
with the statement of this test result affecting their ability to find a partner (p-value = 0.028) as 
well as the ability to find/keep a job (p-value = 0.004). Those of Asian ethnicity were the most 
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likely (p-value = 0.006) to disagree/strongly disagree that this test result would impact their 
decision about having children. Those of Native Hawaiian or Pacific Islander ethnicity were the 
most likely (p-value = 0.041) to disagree/strongly disagree that this test result would affect 
everyday life and those of American Indian or Alaskan Native ethnicity were the most likely to 
agree/strongly agree that this test result would affect everyday life. However, there were only 2 
participants of Native Hawaiian or Pacific Islander ethnicity and only 4 participants of American 
Indian or Alaskan Native ethnicity and these statements and result for these groups may not 
apply to that ethnic group as a whole. 
Those who reported a household income of less than $10,000 were the least likely (p-
value = 0.001) to disagree/strongly disagree that this test result would affect their ability to find a 
partner as well as the least likely (p-value = 0.001) to disagree/strongly disagree that this test 
result would affect their ability to find/keep a job and the most likely (p-value = 0.012) to 
agree/strongly agree that this test result would affect their everyday life. 
Those who strongly disagreed with the statement “religion is an important part of my 
life” were the most likely (p-value = 0.021) to disagree/strongly disagree that this test result 
would affect their ability to find/keep a job as well as the most likely (p-value = 0.036) to 
disagree/strongly disagree that this test result would affect their everyday life and the least likely 
(p-value = 0.001) to agree/strongly agree that they would talk about this gene/test result with 
their family. 
Region of residence in the United States was shown to have statistically significant 
differences between regions for the statements of ability to find a partner (p = 0.002) and ability 
to find/keep a job (p = 0.003) for this scenario. The extremes were again found in the groups of 
those residing in Alaska/Hawaii or a US Territory, with the 2 participants in Alaska or Hawaii 
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being the most likely to disagree/strongly disagree that this test result would affect their ability to 
find a partner or find/keep a job and the 2 participants in a US Territory being the most likely to 
agree/strongly agree that this test result would affect their ability to find a partner or find/keep a 
job. Because of the almost negligible amount of participants in these two groups, it is not likely 
that these differences would be applicable to the population at large in these two regions. 
The sex of the participants, significant family history of cancer, personal history of 
cancer, military service, knowledge/understanding of genetics, marital status, and political views 
were not proven to have significant differences between groups.  
4.4.5 Scenario 5 
SCENARIO: You go through comprehensive genetic testing for cancer genes and are found 
to be negative for any changes in the genes that we can test for at this time. Although the 
test indicates that you are likely not at an increased risk for cancer, it is important to 
remember that most cancers are not hereditary, meaning that they are not caused by a 
change in a gene that can be passed down through families. As a result, you still could 
develop cancer in the future, but your risk is likely similar to other people in the general 
population. 
 
Table 9 illustrates the full results from the Likert-scale questions in this scenario. In this 
scenario, 64.08% (n = 863) of respondents agreed or strongly agreed with the statement, “I 
would continue regular, early-detection screenings for cancer (mammograms, prostate exams, 
pap smears, etc.).  More than half of respondents (73.24%, n = 863) answered either “disagree” 
or “strongly disagree” to the statement, “this test result would affect my everyday life.” The 
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majority of participants (74.39%, n = 863) disagreed or strongly disagreed with the statement 
“this test result would affect my mental health.”  The majority of participants (59.10%, n = 863) 
agreed or strongly agreed with the statement “I would talk to my family about this test result.” 
 
Table 17: Scenario 5 Likert Scale Results (n = 863) 
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4.4.5.1 Comparison of Demographics for Scenario 5 
Table 18: Scenario 5 Statistically Significant Differences in Demographic Groups  
Statement Demographic p-value 
I would continue regular, 
early-detection screenings for 
cancer 
Sex 0.005 
Knowledge of Genetics 0.042 
Political Views 0.043 
This test result would affect 
my everyday life 
Family History of Cancer 0.039 
Genetic Testing Experience 0.039 
This test result would affect 
my mental health. 
Level of Education 0.003 
Region of Residence 0.016 
I would talk to my family 
about this gene and my test 
result 
Sex 0.038 
Family History of Cancer 0.028 
Marital Status 0.040 
Level of Religiosity 0.001 
Political Views 0.009 
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There was a statistically significant difference between sexes for the statement “I would continue 
regular, early-detection screenings for cancer (mammograms, prostate exams, pap smears, etc.)” 
(p = 0.005). There was also a statistically significant difference between sexes for the statement 
“I would talk to my family about my test result” (p = 0.038). Females were more likely to agree 
or strongly agree with both of these statements.  
 The presence or absence of a significant family history of cancer showed some 
statistically differences in their answers for whether this test result would affect everyday life (p 
= 0.039) and whether they would talk to their family or not about these results (p = 0.028). 
Having had or not had genetic testing before had a statistically significant difference between 
groups for whether this test result would affect everyday life (p = 0.039). 
 The level of knowledge and/or understanding of genetics showed a statistically 
significant difference between groups for whether they would get the regular screenings for 
cancer currently available (p = 0.042). Those who ranked their knowledge/understanding as 
“excellent” were the most likely to agree/strongly agree that they would continue regular cancer 
screenings given a negative result. 
Both the level of education and the region of residence in the United States showed a 
statistically significant difference between groups using a one-way ANOVA test for whether this 
test would affect mental health. The group of participants with some college/no degree were the 
most likely (p = 0.003) to disagree/strongly disagree that this result would affect their mental 
health. Those in the Southwest region of the United States were the most likely (p = 0.016) to 
disagree/strongly disagree that this result would affect their mental health. 
 Marital status showed a statistically significant difference between groups for whether 
they would talk to their family about the test result (p = 0.040). Those who were married were 
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the most likely to agree/strongly agree that they would talk about this test result with their 
family.  
Level of religiosity also showed a significant difference between groups for whether they 
would talk to their family (p = 0.001) as well as showing a difference between groups for if this 
result would affect their everyday life (p = 0.048). Those who strongly disagreed with the 
statement “religion is an important part of my life” were the least likely to agree/strongly agree 
that they would talk with their family about this test result. Those who were widowed were the 
most likely to disagree/strongly disagree that this test result would affect their everyday life. 
Political views showed a statistically significant difference between groups for whether 
they would continue to get the regular screenings for cancer and whether they would talk to their 
families about the test result. Those who were liberal were the most likely (p = 0.043) to 
agree/strongly agree that they would continue to get regular screenings for cancer. Those who 
were moderate were the least likely (p = 0.009) to agree/strongly agree that they would talk to 
their family about these results.  
 Military service, personal history of cancer, race/ethnicity, and income level were all 
demographics that did not show a statistically significant difference between groups in this 
particular scenario. 
4.4.6 Scenario 6 
SCENARIO: You go through comprehensive genetic testing for cancer genes and are found 
to be negative for any changes in the genes that we can test for at this time. (0% increased 
risk for hereditary cancer, your risk is likely similar to the general population).  However, 
15 years later, you are diagnosed with cancer. 
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Table 14 illustrates the full results from the likert-scale questions in this scenario. In this 
scenario, 54.01% (n = 861) of respondents disagreed or strongly disagreed with the statement, “I 
would have negative feelings about the genetic testing I had done.” A somewhat similar number 
of participants agreed/strongly agreed (39.37%, n = 861) as did disagree/strongly disagree 
(45.41%, n = 861) with the statement “I would question the accuracy of the genetic testing I had 
done.” The majority of participants disagreed/strongly disagreed (52.49%, n = 861) with the 
statement “I would have negative feelings about genetic testing in general.” More than half of the 
participants agreed/strongly agreed (50.75%, n = 861) with the statement “I would want to be 
retested.” 
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4.4.6.1 Comparison of Demographics for Scenario 6 
Table 20: Scenario 6 Statistically Significant Differences in Demographic Groups 
Statement Demographic p-value 
I would have negative 
feelings about the genetic 
testing I had done 
Rank Knowledge 0.021 
Race/Ethnicity <0.001 
Income 0.004 
Political Views 0.007 
I would question the accuracy 
of the genetic testing I had 
done 
Education Level 0.039 
Race/Ethnicity 0.002 
Political Views 0.036 
I would have negative 
feelings about genetic testing 
in general 
Rank Knowledge 0.005 
Education Level 0.008 
Race/Ethnicity <0.001 
Level of Religiosity 0.018 
Political Views <0.001 
I would want to be retested Sex 0.045 Education Level 0.017 
 
Males were more likely (p-value = 0.045) to agree/strongly agree that they would want to be 
retested. Those who ranked their knowledge/understanding of genetics as “poor” were the most 
likely to agree/strongly agree that they would have negative feelings towards this particular 
testing (p-value = 0.021) as well as for genetic testing in general (p-value = 0.005). Those with a 
high school/GED education or less were the most likely to agree/strongly agree that they would 
question the accuracy of the genetic testing they had undergone (p-value = 0.039) as well as have 
negative feelings about genetic testing in general (p-value = 0.008) and were also the most likely 
to agree or strongly agree that they would want to be retested (p-value = 0.017). 
Those who answered the race/ethnicity demographic question as “other” were the most 
likely (p-value = <0.001) to agree/strongly agree that they would have negative feelings about 
the cancer genetic testing they had undergone and were the most likely (p = 0.002) along with 
those of black/African American ethnicity to question the accuracy of the genetic testing. Those 
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of black/African American ethnicity were the most likely (p = <0.001) to have negative feelings 
about genetic testing in general. Those who were conservative were the most likely (p = 0.007) 
to agree/strongly agree that they would have negative feelings about the cancer genetic testing, to 
question the accuracy of the testing (p = 0.036), and to have negative feelings about genetic 
testing in general (p = 0.002).  
Those with a household income of $50,000 - $74,999 were the most likely (p = 0.004) to 
agree/strongly agree that they would have negative feelings towards the cancer genetic testing.  
Participants who answered “neither agree nor disagree” with the statement of “religion is an 
important part of my life” were the most likely to agree/strongly agree (p = 0.018) that they 
would have negative feelings about the cancer genetic testing. 
Significant family history of cancer, personal history of cancer, experience of having 
genetic testing, military service, marital status, and region of residence in the United States were 
all demographics that were not shown to have statistically significant differences between groups 
for this specific scenario. 
4.5 DESIRED METHOD OF ORDERING  
The participants who indicated at the end of the survey that they would either want to take a 
genetic testing like this at some point (either immediately or possibly in the future) were asked 
what their preferred way of ordering this test would be. The options were “Direct to Consumer,” 
“Through my Primary Care Physician,” and “Through a Genetic Counselor.” The majority of 
participants (50.77%, n = 778) indicated that they would prefer to order this test through their 
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PCP. A similar number of participants indicated that they would prefer to order this test Direct-
to-Consumer (25.32%, n = 778) as through a genetic counselor (23.91%, n = 778).  
 
 
Figure 2: Preference of Ordering Provider 
4.5.1 Thematic Analysis of Ordering Method 
Some of the participants interpreted the last question of “why would you want to take a genetic 
test like this” as why they would want to order the test through DTC, PCP, or GC (depending 
what answer option they chose. This was not the original intent of the question, but incidentally 
provided a different aspect to the data to analyze and explained the through processes of why 
they would want to order a genetic test like this through direct to consumer testing, through their 
primary care physician, or through a genetic counselor. In total, 201 participants obviously 
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itself and why they chose their answer. These answers were coded separately than the other 
responses to identify themes specific to that specific interpretation of the question. 
 Thematic analysis was performed on these coded answers. Major themes identifed 
relating to ordering preference were: 1) trust/relationship with provider, 2) desire for a specialist 
or expert in the field, 3) privacy, 4) convenience/time, 5) cost, and 6) accuracy. Prevalence of 
each theme was calculated (Table 15). Quotes from survey respondents exemplifying each theme 
are illustrated in Table 16.  
Table 21: Prevalence of Identified Themes 
Theme n (%), n = 201 
Trust and/or relationship with provider 54 (26.87) 
Desire for specialist and/or expert in the field 51 (25.37) 
Privacy 17 (8.46) 
Convenience/Time 40 (19.90) 
Cost 15 (7.46) 
Accuracy 18 (8.96) 
 
Table 22: Participant Quotes 
Theme Quote 
Trust and/or relationship 
with provider 
“I know my primary care physician and we have a good relationship. Doing 
this test with them would make me feel comfortable, and I know my doctor 
would do a nice job explaining the results of the test to me.” 
Desire for specialist 
and/or expert in the field 
“This is specialized data that requires interpretation. A professional who has 
practice reading this data would be more able to properly explain the 
results.” 
Privacy “It would be more private and no insurance involved to label me” 
Convenience/Time “It’s easy, I don’t have to go anywhere to get it done. I can do it on my 
time.” 
Cost “Because it’s probably cheaper by bypassing the doctor” 
Accuracy “It seems to have the least chance for any errors or variables to skew/alter the 
results.” 
 67 
5.0  DISCUSSION 
This study was designed to collect data on the interest level and motivations of individuals from 
Amazon Mechanical Turks regarding genetic testing for hereditary cancer syndromes. The 
interest level and motivations were elicited from participants both before and after more 
information about the possible result of a test like this were divulged. In addition, the second 
objective of the study was to collect data on possible psychosocial impacts of a program of 
genetic testing in the general population. This study’s findings, along with future studies, will aid 
in filling a gap in the literature about the interest of individuals in the general population for 
population-based cancer genetic testing. The findings also point out other elements that need to 
be considered when implementing such a program.  
5.1 INITIAL INTEREST LEVEL FOR CANCER GENETIC TESTING 
The first aim of the study was to examine the interest level of individuals in the Amazon Turks 
Community in taking a genetic test for hereditary cancer. Analysis of the survey data indicate 
that the majority of participants were initially interested in personally taking a genetic test for 
hereditary cancer genes at this point in time. Only 6% of participants initially indicated that they 
would never be interested in taking a genetic test for hereditary cancer genes.  
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The survey question eliciting initial interest referred to all known cancer genes in order to 
make the test applicable to all, though BRCA1/2 would most likely be the only genes first offered 
in a population-screening approach based on current discussion in the literature. It was decided 
to include all known cancer genes instead of focusing on only BRCA1/2 so as to make the survey 
more obviously applicable to all participants, specifically men. There was also a simplicity factor 
in not having to go into detail about specific genes. It would be an interesting follow-up study to 
focus specifically on interest and attitudes towards BRCA1/2 testing. 
It was interesting that most of the individuals in the study desired to take a genetic test 
like this simply because they want to know or are curious about this information. Additionally, 
many respondents were also interested in knowing this information so they could possibly take 
preventative measures or indicated that they would make lifestyle changes if they knew they 
were at a higher risk of a certain type of cancer. Other studies have found that members of the 
general population are interested in genetic testing for similar reasons71,72. A study by Henneman 
et al., 200672 surveyed the Dutch population and found that 52% of their participants would want 
to know their risks of certain diseases in order to prevent them and 34% of participants would 
want genetic testing because they are curious about their “genetic make-up”72. 
5.2 COMPARING THE SCENARIOS 
The second aim of the study was to identify some possible psychosocial implications in the 
context of a population-screening program for hereditary cancer. The scenarios were presented to 
participants immediately after the initial question of interest.  
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5.2.1 Risk Level Scenarios 
In comparing the three mutation-positive results, one where the lifetime risk of a certain cancer 
was increased to 15 – 25%, one where the lifetime risk was increased to 50%, and one where the 
lifetime risk was increased to 80%, the percentage of participants who agreed/strongly agreed 
with the psychosocial implication statements almost follow an exponential curve (Figure 3). For 
each of the statements, the lowest percentage of participants who agreed/strongly agreed with the 
psychosocial implication statement was found at the 15 – 25% level, and the highest percentage 
of participants who agreed/strongly agreed with the psychosocial implication statement was 
found at the 80% level. This intuitively makes sense, as one would expect a positive result to 
possibly affect one’s life more, if the lifetime risk of cancer is higher.  
 










































5.2.2 VUS Scenario 
 
Figure 4: VUS Scenario Results 
 
The likert-scale results of a variant of uncertain significance in a gene associated with an 
increased risk in hereditary cancer are depicted in Figure 4. These results followed a similar 
pattern as the ‘increased risk of a certain cancer to 15 - 25%,’ though the percentage of 
participants who agreed or strongly agreed with each of these statements was slightly less than 
the 15 - 25% increased risk scenario. Approximately 22% of participants agreed or strongly 
agreed that a VUS result would affect their everyday life and approximately 27% of participants 
agreed or strongly agreed that this test result would affect their mental health. This may be 
concerning for a population-based screening program as currently at least 1.6% of participants in 






























consistent with reported data. A study by Vos et al., 200873 was conducted of patients with a 
VUS and found that a third (n = 24) of their participants reported “large changes in specific life 
domains.” There is some evidence to suggest that carriers of a VUS in a hereditary cancer gene 
may have a misperception and make radical medical decisions based on this VUS41. This is 
greatly concerning as it is a recommendation that patients should not make medical decision 
based on a VUS74. Hopefully attempts to make surgical decisions based on a VUS would be 
halted by either physicians or insurance companies, but it may prove difficult to ensure this.  
5.2.3 Negative Result Scenarios 
5.2.3.1 Negative Genetic Testing Results 
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Figure 5 demonstrates the percentage of participants who agreed or strongly agreed on a likert-
scale to three of the statements given. One of the more concerning findings of this study would 
be that only 64% of participants agreed or strongly agreed with the statement “I would continue 
regular, early-detection screenings for cancer (mammograms, prostate exams, pap smears, etc.).” 
This is an important point to consider when weighing the benefits and risks of a population-
based screening program. If a substantial number of participants of such a program are going to 
decide to not have the recommended cancer screenings if they test negative for hereditary cancer 
genes, the positive effects of a program may be negated or the effects may prove to be harmful 
overall for cancer prevention. However, it is important to note one of the limitations of the study, 
which is that this is a hypothetical question. Faced with an actual test result and physician 





5.2.3.2 Negative Genetic Testing Result, Diagnosis of Cancer 15 Years Later 
 
Figure 6: Negative Genetic Test, Cancer Diagnosis Later - Likert Scale Results 
 
This scenario described the participant testing negative for mutations in the known hereditary 
cancer genes, but then getting a diagnosis of cancer 15 years later. The results of the likert-scale 
statements show a concerning trend of possible negative feelings about genetic testing. There 
may be additional negative emotions towards healthcare providers and the medical field in 
general. This is speculation, as these specific questions were not asked. More than half of 
participants agreed or strongly agreed that they would want to be retested, which illuminates the 
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5.3 INTEREST LEVEL AFTER THE SCENARIOS 
When comparing the interest level in taking a genetic test such as this after the participants 
answered questions related to the six scenarios to the initial interest level question, there were 
more participants who answered (9.64%, n = 861) that they would “never take a test like this” 
and answered (25.44%, n = 861) “currently not interested, but would consider it in the future” 
and less who answered (64.92%, n = 861) “yes, I would take this test today if I could.” The 
majority of participants were still interested in taking a test like this either immediately if 
possible or at some point in the future (90.36%, n = 861).  
5.4 STUDY FINDINGS IN THE CONTEXT OF PREVIOUS WORK 
The vast majority of studies that have collected data on the possibility of population screening 
for hereditary cancer genes, specifically BRCA1/2 have focused on the prevalence of mutations 
in families with unremarkable cancer history or on cost-effectiveness of population-screening 
compared to a family-history based approach75,76.  
Based on an extensive literature search, this appears to be the first reported data on 
whether individuals in the general population in the United States would be interested in being 
offered a genetic test like this. There was a study conducted in the Dutch population that 
assessed interest in genetic testing for cardiovascular disease, cancer, dementia, and diabetes71. 
This data fills part of a gap in the literature relating to the desire of individuals in the general 
population to have this type of genetic testing available on a broader scale than current methods 
allow. 
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5.5 IMPORTANCE OF GENETIC COUNSELING 
One of the primary aims of genetic counseling in a cancer setting is to ensure that the informed 
consent elements previously discussed in the background are present and understood by the 
individual considering genetic testing for cancer susceptibility. Many of these basic elements 
would be difficult to establish in a population-screening based approach and may pose an ethical 
barrier for a population-screening program for cancer susceptibility. This may be an ethical 
barrier because informed consent has been shown to be an important aspect of patient autonomy. 
This study showed that the majority of our participants were interested, but that the interest level 
changed in some individuals after more information was gained about possible results. It may be 
beneficial to study if interest levels in genetic testing change with a formal informed consent 
process. 
Genetic counselors have specialized training to ensure that the proper informed consent is 
present in a session as well as the ability to assess how well the patient is understanding the 
information related to genetic testing. In a face-to-face session, genetic counselors are also able 
to ask questions relating to the psychological state of the patient and his/her social support and 
provide referrals and resources. Given the current limited number of genetic counselors, pre-test 
counseling by genetic counselors would not be plausible for a population-screening program. 
Genetic counseling outcomes been reported on in the literature and has been shown to be 
valuable in terms of patient satisfaction, knowledge, and understanding55. Specific outcomes 
found in the ABOUT study by Armstrong et al.55 show the increased satisfaction of patients who 
had pre-test counseling by genetic counselors compared to physicians.  
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5.6 STUDY LIMITATIONS 
One of the study limitations was a lack of robust qualitative data. In the open-ended qualitative 
questions, many respondents used a few words or a sentence to answer the question. Because of 
the nature of a survey rather than a focus group or an interview, robust qualitative data is 
typically difficult to obtain. This made thematic analysis difficult as broader themes outside of 
the codes themselves were not exactly feasible.  
It was revealed through data analysis that the order of the open-ended question of 
Q54:“why did you decide you would want to take a genetic test like this?” was poorly placed 
after Q50: “what would your preferred way of ordering this test be?” instead of Q54: “after going 
through the various scenarios of possible outcomes for genetic testing, would you be interested 
in taking a comprehensive genetic test that could identify a hereditary risk of cancer?” This mis-
ordering of questions caused participants to not consistently interpret the question. Many 
interpreted it as it was intended as to elicit an elaboration on their interest level, however, many 
other interpreted as to why they chose their preferred ordering method. However, this mistake 
led to the gathering of useful and interesting data, and if the survey were repeated, participants 
would be asked to elaborate on their preferred ordering method.  
Amazon Mechanical Turks was a convenience sample and not perfectly representative of 
the general population of the United States. While other studies on the demographics of Amazon 
Mechanical Turks have shown it to be more representative than other convenience samples of 
college students, it is still a convenience sample and certain groups are underrepresented while 
other groups are overrepresented. This is a limitation of the findings of this study may not be 
fully applicable to the actual general population. 
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An additional limitation of this study is that it asked about a hypothetical situation and 
there are studies that show that individuals may have different opinions or ideas when presented 
with an actual genetic test. Further studies could calculate interest levels and motivations in a 
real-life situation and possibly compare these to the hypothetical findings from this study. 
5.7 FUTURE STUDIES 
A future study eliciting the interest level of taking a genetic test for only BRCA1/2 would be 
interesting to see if there are differences than the interest level in this study. If possible, another 
study relating to the interest level and psychosocial implications on a sample more representative 
of the general population may be useful to compare to the findings of this study. 
More research needs to be conducted in the form of studies with large sample sizes to 
work out the proper infrastructure needed for a population-screening program of cancer genes. 
These studies could specifically collect data on possible forms of informed consent (ex. Video, 
quizzes, interactive website, etc.) that are the most effective, best way to disclose results, how to 
best triage participants based on results for future medical care, and specific resources for 
participants.  
Future studies should also focus on how best to properly convey the results of the genetic 
test to participants in order to ensure proper understanding of these results in the context of their 
future medical management, in the case of the possible results of a positive, negative, or VUS. 
Part of the results disclosure may also need to be able to assess the psychological state of the 
participant and have the ability to offer appropriate resources such as support groups or therapists 
and follow up with the participant as needed. Long-term studies could track participants and 
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collect data regarding the adherence to medical management recommendations concerning 
appropriate cancer screening procedures in the case of all possible test results as well as any 
psychosocial implications. 
5.8 BASIC ELEMENTS NEEDED BEFORE THE IMPLEMENTATION OF A 
POPULATION SCREENING PROGRAM 
The significant reductions in cancer risks associated with preventative measures1 offered to those 
known to be at a high-risk of cancer highlights the importance of identifying mutation carriers. 
However, several problems present themselves when posing a program of population screening. 
The benefits and risks should always be weighed before the implementation of such a program. 
Future clinical research studies should take place to determine what specific extensive 
infrastructure is necessary to have in place before a population-screening program for hereditary 
cancer genes is implemented. Examples of the specific extensive infrastructure would most 
likely include the following: how results would be communicated, how to manage participants 
appropriately based on results, how to provide education on what their results mean for them and 
how to communicate with family members about results, what testing laboratory would be used, 
and resources such as support groups and hotlines for questions from participants. This 
infrastructure will be necessary in order to ensure that the possible benefits of such a program 
outweigh the possible risks. Streamlined mechanisms for the clinical management of BRCA1/2 
mutation carriers would be essential for the success of a population-screening program.  
The elements and current standards for informed consent prior to cancer susceptibility 
testing should still be part of a population screening approach to genetic testing. This informed 
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consent would most likely need to look differently than a genetic counseling pre-test session 
currently does, simply because of the lack of manpower. Recent reports in the media have 
specifically highlighted this shortage. National Public Radio (NPR) summarized the shortage of 
genetic counselors and discussed how there are currently approximately 650 job openings for 
less than 300 new genetic counseling graduates77. This study showed the importance of informed 
consent as part of any genetic testing, as a subset of the participants indicated a different level of 
interest after learning more about possible results and processing how this could affect their life.  
Given the possibility of reclassification of a VUS to a pathogenic mutation, strong 
consideration should be given to whether these results are reported or not. Medical, ethical, and 
legal issues arise if these results are not reported, while psychosocial and possible medical issues 
arise if these results are reported. A reliable system for re-contacting in the case of a VUS when 
it is reclassified is necessary in either case, particularly for those VUS results that are reclassified 
as positive. In the case a population screening program that does not report out VUS results, 
negative results would not need to be called out to patients as they were already told they were 
negative. This study shows that there is at least a subset of individuals may experience 
psychosocial effects such as an impact on mental health due to a VUS result.  
5.9 PUBLIC HEALTH IMPACT 
Population-based screening for hereditary cancer syndromes would have the ultimate goal of 
eventually eliminating the portion (5-10%) of the cancer burden that consists of hereditary 
cancers. This could have a substantial impact on multiple aspects of healthcare. Population-based 
screening has the potential ability to prevent cancer entirely or detect it at an early stage. This 
 80 
prevention and early detection of hereditary cancer could both save lives and improve the quality 
of life for those that may have otherwise had to endure substantial medical bills and/or extensive 
treatment in the form of chemotherapy, radiation, surgery, etc. 
 If it were possible to appropriately manage all hereditary cancer syndrome mutation 
carriers through prevention and early detection in the general population, there may be a 
significant public health impact in terms of cost-effectiveness, patient waitlists for oncology 
clinicians, quality adjusted life years (QALYs) of the patients, rates of hospitalization, 
measurement of disability, and others. Some of these public health impacts may be difficult to 
measure, particularly in the case of hereditary cancer gene mutations, which are not 100% 
prevalent. Long-term studies would most likely be needed to truly measure the public health 
impact in meaningful ways. 
 There is also a possibility of negative public health impacts should a population-based 
screening program be implemented. The possible negative effects could include a false sense of 
security of mutation-negative patients, increased psychological distress in patients with variants 
of uncertain significance or pathogenic mutations, an increased patient load for certain clinicians, 
the possibility of the mismanagement of patients due to infrastructure problems or 
misinformation on the part of healthcare providers and/or patients. It would also be very difficult 
to measure overall cost-effectiveness as those that may have died from cancer would most likely 
have other health-related costs as they age. 
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6.0  CONCLUSION 
Overall, this study found that the majority of participants were interested in taking a genetic test 
that could identify a hereditary predisposition to cancer. However, the interest levels changed 
somewhat after the presentation of the scenarios, implying that individuals may have different 
opinions about such testing when more information is learned about the test one would be 
undergoing. Motivations for why an individual would be interested in testing either now or 
possibly in the future were identified using thematic analysis. The largest proportion of 
participants (59.81%) simply wants to know this information. Motivations for why an individual 
would not be interested in testing were also identified using thematic analysis and the largest 
proportion (34.38%) of participants stated psychological stress/anxiety as the reason why they 
would not want this test. Even at the lowest risk level of an increased risk of 15 – 25% of a 
certain cancer, a negative result, and a result of a variant of uncertain significance (VUS), 
participants noted psychological and psychosocial implications of these results. The ultimate 
benefit of a population-based screening program would be to have the ability to identify more 
mutation-carriers and manage them appropriately. Appropriate management of mutation-carriers 
to prevent cancer and save lives should be weighed against the risks of the psychological, 
medical, legal, economic and ethical issues that currently surround such a program. More studies 
with large sample-sizes are needed in the general population to work out these issues before a 
program like this is implemented on a clinical, state or nation-wide scale. 
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APPENDIX B: SURVEY 






[Anyone who answered “no” was not eligible to take the survey and taken to a “thank you” page] 
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[Only asked to participants who answered “Yes, I would take this test today if I could”] 
[Only asked to participants who answered “No, I would never take a test like that”] 





                
       
[Only asked to participants who answered “Strongly Disagree” to the statement “I would talk to my 
family about this gene and my test result] 
[Only asked to participants who answered “Disagree” to the statement “I would talk to my family 




                
       
[Only asked to participants who answered “Strongly Disagree” to the statement “I would talk to my 
family about this gene and my test result] 
[Only asked to participants who answered “Disagree” to the statement “I would talk to my family 






                
       
[Only asked to participants who answered “Strongly Disagree” to the statement “I would talk to my 
family about this gene and my test result] 
[Only asked to participants who answered “Disagree” to the statement “I would talk to my family 




                










[Only asked to participants who answered “Yes, I would take this test today if I could” to Q49.]  
[Only asked to participants who answered  “Currently not interested, but would consider it later in 
life” to Q49.]  
[Only asked to participants who answered “No, I would never take a test like that” Q49.]  
[Only asked to participants who answered  “Yes, I would take this test today if I could” to Q49.]  
[Only asked to participants who answered “Currently not interested, but would consider it later in 
life” to Q49.]  
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